## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-05-12_Virtual Town Hall 55_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/148740/download?attachment
link youtube: https://youtu.be/toEiWI_d-m8
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Updates on COVID-19 Testing and Submissions Priorities

QA Block 1-1
CLARIFIED QUESTION: Do saliva collection devices or specimens added to VTM prior to testing need an EUA?
CLARIFIED ANSWER: Yes, saliva collection devices or specimens added to VTM prior to testing require FDA authorization through EUA or full premarket review, as no FDA-cleared saliva collection devices exist for viral RNA. The FDA has issued three EUAs for such devices, and developers should review these authorizations and related templates for guidance.
VERBATIM QUESTION: Do saliva collection devices or specimens added to VTM prior to testing need an EUA?
VERBATIM ANSWER: There currently are no FDA cleared or approved saliva collection devices intended for use with viral RNA. Since these are not 510k exempt devices FDA authorization either through full premarket review or through EUA is required for these saliva collection devices. We have to date issued three EUA as I believe for saliva collection devices for use with SARS CoV-2 tests. And we recommend that you look at the authorization documents for those three EUAs as a reference point. Additionally, the home specimen collection molecular diagnostic template includes some recommendations including four analytical and clinical studies that may be applicable even if the selection - or sorry a unintelligible saliva collection device is not intended to be used for home specimen collection specifically.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Saliva collection devices, EUA requirements, FDA guidance
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: What are the FDA's current priorities for COVID-19 diagnostic testing?
CLARIFIED ANSWER: The FDA's current priorities for COVID-19 diagnostic testing include amendments for pooling and screening asymptomatic individuals to increase testing access, focusing on point-of-care, at-home collection, and central lab high-throughput diagnostic tests to expand testing capacity, reduce turnaround times, and manage the virus effectively, particularly in work and school environments.
VERBATIM QUESTION: What are the FDA's current priorities for COVID-19 diagnostic testing?
VERBATIM ANSWER: First I want to go over our current priorities. They remained largely obvious and unchanged. Of course we've issued new amendments recently pooling and screening asymptomatics. And for those tests that qualify for those amendments those are obviously priorities for us because they're both designed to increase access substantially for testing. And of course our continued focus on particularly on diagnostic tests for point of care in home and home collection of diagnostic tests remains top priority and as well central lab tests that are extremely high throughput tests. All of these again are designed to increase access to testing and hopefully decrease turnaround time and better and folks are better able to manage this virus and in particular as they go to work and go to school and as we prepare going back to school in the fall.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 diagnostic priorities, pooling and symptom screening, point-of-care and high-throughput testing
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: Are amendments such as those for pooling and asymptomatic screening considered high priorities for FDA review?
CLARIFIED ANSWER: Amendments for pooling and asymptomatic screening are high priorities for FDA review as they aim to significantly increase testing access.
VERBATIM QUESTION: Are amendments such as those for pooling and asymptomatic screening considered high priorities for FDA review?
VERBATIM ANSWER: Of course we've issued new amendments recently pooling and screening asymptomatics. And for those tests that qualify for those amendments those are obviously priorities for us because they're both designed to increase access substantially for testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: amendments, FDA review priorities, asymptomatic screening
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: How should test developers approach obtaining feedback on plans for converting to full authorization if they submit a Pre-Submission (Pre-Sub)?
CLARIFIED ANSWER: Test developers should submit a Pre-Submission (Pre-Sub) for feedback on plans to convert to full authorization. The FDA is reviewing these submissions but may exceed standard timelines due to COVID-related workload.
VERBATIM QUESTION: How should test developers approach obtaining feedback on plans for converting to full authorization if they submit a Pre-Submission (Pre-Sub)?
VERBATIM ANSWER: So for those developers who want to see feedback on their proposed plans for converting to full authorization we are accepting Pre-Subs and we are reviewing Pre-Subs. We would ask as with all other full authorization sort of submissions typically we're doing our best to hit our MDUFA guidelines for times but we are swamped and we're going to do our best to try to hit those usual timelines but in some cases if not many we're going to have to go a bit longer due to the workload and continuing workload for COVID.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-Submission process, Full authorization, COVID-related workload
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What types of Pre-Submissions is the FDA currently reviewing for COVID-related diagnostics?
CLARIFIED ANSWER: The FDA is currently reviewing select categories of Pre-Submissions, specifically COVID-related pre-submissions, for feedback on plans to transition to full authorization.
VERBATIM QUESTION: What types of Pre-Submissions is the FDA currently reviewing for COVID-related diagnostics?
VERBATIM ANSWER: We are reviewing a select categories of Pre-Subs. These are not pre-EUAs. These are normal well submissions sort of pre-submissions. And they include COVID related pre-submissions. So for those developers who want to see feedback on their proposed plans for converting to full authorization we are accepting Pre-Subs and we are reviewing Pre-Subs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-Submissions, COVID-related diagnostics, FDA review process
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: What timelines should developers expect for MDUFA reviews, given the agency's stated workload challenges?
CLARIFIED ANSWER: FDA aims to follow MDUFA timelines but due to workload challenges, some reviews may take longer.
VERBATIM QUESTION: What timelines should developers expect for MDUFA reviews, given the agency's stated workload challenges?
VERBATIM ANSWER: And we are reviewing a select categories of Pre-Subs. These are not pre- EUAs. These are normal well submissions sort of pre-submissions. And they include COVID related pre-submissions. So for those developers who want to see feedback on their proposed plans for converting to full authorization we are accepting Pre-Subs and we are reviewing Pre-Subs. We would ask as with all other full authorization sort of submissions typically we're doing our best to hit our MDUFA guidelines for times but we are swamped and we're going to do our best to try to hit those usual timelines but in some cases if not many we're going to have to go a bit longer due to the workload and continuing workload for COVID.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: MDUFA review timelines, FDA workload challenges, Pre-Submission reviews
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: What options are available for developers interested in long-term market presence of SARS CoV-2 molecular tests under the 510k pathway?
CLARIFIED ANSWER: FDA encourages developers aiming for long-term market presence with SARS CoV-2 molecular tests to pursue submissions under the 510k pathway after the authorized de novo. They should prepare for full authorization by acquiring or banking necessary samples for analytical and clinical validation.
VERBATIM QUESTION: What options are available for developers interested in long-term market presence of SARS CoV-2 molecular tests under the 510k pathway?
VERBATIM ANSWER: For molecular, for the lion's share of molecular tests we've already authorized one de novo and that means all subsequent molecular submissions for SARS CoV-2 whether they be single analyte for SARS CoV-2 or a multi-analyte panel, they all, you know, they meet the other criteria, fall under that, the new pathway, continue with the 510k. For serology and for antigen tests, the first submissions will be de novo. Thereafter the lion's share of those will then also be 510ks. So we do actually urge folks developers who want to be in the market long term with the SARS CoV-2 test to begin turning their attention to this and preparing for full authorization and in particular making sure that they have the samples needed or banking of samples is allowed to do all the analytical work as well as the clinical validation that we expect for those full authorizations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 510k pathway, SARS CoV-2 molecular tests, Full authorization preparation
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What is required for developers to prepare for full authorization of COVID-19 diagnostic tests, including sample banking and validation studies?
CLARIFIED ANSWER: Developers aiming for full authorization of SARS-CoV-2 tests should bank sufficient samples and conduct the required analytical and clinical validation studies.
VERBATIM QUESTION: What is required for developers to prepare for full authorization of COVID-19 diagnostic tests, including sample banking and validation studies?
VERBATIM ANSWER: We do actually urge folks developers who want to be in the market long term with the SARS CoV-2 test to begin turning their attention to this and preparing for full authorization and in particular making sure that they have the samples needed or banking of samples is allowed to do all the analytical work as well as the clinical validation that we expect for those full authorizations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 diagnostic full authorization, Sample banking, Validation studies
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: How does the FDA recommend developers address potential difficulties in obtaining positive samples for validation as infection rates decline?
CLARIFIED ANSWER: The FDA advises developers to prioritize securing necessary samples for full validation now, as infection rates may decline further, making positive samples harder to obtain.
VERBATIM QUESTION: How does the FDA recommend developers address potential difficulties in obtaining positive samples for validation as infection rates decline?
VERBATIM ANSWER: We hope that the, you know, there's what of about 40,000 new infections a day in the US right now, it's still substantial. We do hope that that continues to fall and it falls greatly. So we have seen following prior emergencies where developers when they turn attention to moving towards a full authorization, the positive samples fell off and they struggled at times at forgetting positive samples. So I just bring that up because I think, you know, the FDA is obviously interested in full authorizations and I think developers are too and I wanted to bring this up. And I will be probably reminding developers of this relatively frequently going forward.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation sample challenges, Full authorization
REVIEW FLAG: False

QA Block 1-10
CLARIFIED QUESTION: What pathways (e.g., De Novo or 510k) are available for serology and antigen test submissions, and how does this impact subsequent submissions?
CLARIFIED ANSWER: Initial submissions for serology and antigen tests follow the De Novo pathway. Subsequent submissions, in most cases, will follow the 510(k) pathway.
VERBATIM QUESTION: What pathways (e.g., De Novo or 510k) are available for serology and antigen test submissions, and how does this impact subsequent submissions?
VERBATIM ANSWER: For serology and for antigen tests, the first submissions will be de novo. Thereafter the lion's share of those will then also be 510ks.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology and antigen test pathways, De Novo and 510(k) submissions
REVIEW FLAG: False

QA Block 1-11
CLARIFIED QUESTION: What companion diagnostic or breakthrough requests are still being reviewed under the ongoing workload pressures?
CLARIFIED ANSWER: The FDA is continuing to review breakthrough requests, IDE requests, and companion diagnostic requests despite ongoing workload pressures.
VERBATIM QUESTION: What companion diagnostic or breakthrough requests are still being reviewed under the ongoing workload pressures?
VERBATIM ANSWER: So the other piece that we we'll be continuing to review are breakthrough requests, IDE requests and companion diagnostic requests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: breakthrough requests, companion diagnostics, FDA review priorities
REVIEW FLAG: False

QA Block 1-12
CLARIFIED QUESTION: Where can developers find recommendations or templates to guide analytical and clinical studies for saliva-based diagnostic tests?
CLARIFIED ANSWER: Developers can refer to the home specimen collection molecular diagnostic template for recommendations on analytical and clinical studies relevant to saliva-based diagnostic tests, even if not intended for home collection.
VERBATIM QUESTION: Where can developers find recommendations or templates to guide analytical and clinical studies for saliva-based diagnostic tests?
VERBATIM ANSWER: The home specimen collection molecular diagnostic template includes some recommendations including four analytical and clinical studies that may be applicable even if the selection - or sorry a unintelligible saliva collection device is not intended to be used for home specimen collection specifically.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: saliva-based diagnostics, analytical and clinical studies
REVIEW FLAG: False


#### 2. Guidelines for Clinical Studies on Rapid Antigen Tests

QA Block 2-1
CLARIFIED QUESTION: Is it acceptable to perform a clinical study for a lateral flow rapid antigen test in a home setting instead of a simulated home environment?
CLARIFIED ANSWER: Performing a study in a home setting instead of a simulated home environment is potentially acceptable if a high-sensitivity PCR using a nasal specimen is used as a comparator. Saliva or antigen tests are not acceptable comparators.
VERBATIM QUESTION: Is it acceptable to perform a clinical study for a lateral flow rapid antigen test in a home setting instead of a simulated home environment?
VERBATIM ANSWER: So first performing the study in a home setting instead of a simulated home environment is potentially acceptable. However we do recommend a high- sensitivity PCR using a nasal specimen as a comparator. Neither saliva specimens nor antigen tests are acceptable comparators. You should select a high-sensitivity PCR that is authorized for home collection and use the home collection kit with which that selected comparator test is authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Clinical study settings, Rapid antigen tests, Comparator recommendations
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Would FDA allow the use of a saliva-based comparator test even though the lateral flow rapid antigen test in question uses a nasal sample?
CLARIFIED ANSWER: The FDA does not allow saliva specimens or antigen tests as comparators. Developers should use a high-sensitivity PCR test authorized for home collection with the appropriate home collection kit.
VERBATIM QUESTION: Would FDA allow the use of a saliva-based comparator test even though the lateral flow rapid antigen test in question uses a nasal sample?
VERBATIM ANSWER: Neither saliva specimens nor antigen tests are acceptable comparators. You should select a high-sensitivity PCR that is authorized for home collection and use the home collection kit with which that selected comparator test is authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: saliva-based comparator test, nasal sample protocols, clinical study requirements
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: How should developers address the concern of which sample is taken first in studies involving swabs for anterior nares?
CLARIFIED ANSWER: Developers should randomize the collection of swabs to avoid consistently drawing antigen and PCR tests in the same order, and ensure both anterior nares are sampled for each test. Additionally, submit a pre-EUA with the study design to FDA for review.
VERBATIM QUESTION: How should developers address the concern of which sample is taken first in studies involving swabs for anterior nares?
VERBATIM ANSWER: In order to address the concern of which sample is taken first, we recommend that the collection of swabs should be randomized so that the antigen and PCR tests are not consistently drawn in the same order and that both anterior nares should be sampled for each test. We would also recommend that you send in a pre-EUA with your study design and check the comparator selection with FDA prior to initiating your study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Sample collection order, Clinical study protocol, FDA recommendations
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Should developers send a pre-EUA with their study design and check the comparator selection with FDA prior to initiating the study?
CLARIFIED ANSWER: The FDA recommends submitting a pre-EUA with the study design and checking comparator selection with the FDA before starting the study.
VERBATIM QUESTION: Should developers send a pre-EUA with their study design and check the comparator selection with FDA prior to initiating the study?
VERBATIM ANSWER: We would also recommend that you send in a pre-EUA with your study design and check the comparator selection with FDA prior to initiating your study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-EUA submission, comparator selection, study design review
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: What is the recommended time gap between the first collection and the second collection to minimize sensitivity loss for both the comparator and the test device?
CLARIFIED ANSWER: The FDA recommends a gap of 10 to 15 minutes between the first and second collection to avoid sensitivity loss for both the comparator and the test device.
VERBATIM QUESTION: What is the recommended time gap between the first collection and the second collection to minimize sensitivity loss for both the comparator and the test device?
VERBATIM ANSWER: We would recommend that there is a gap between the first collection and the second collection of probably a minimum of ten to 15 minutes. And when we worked with developers before and have done this, we haven't seen a drop off in sensitivity for either the comparator or the test device.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sensitivity loss, collection time gap, diagnostic test protocol
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: Which high-sensitivity PCR tests are authorized for use as comparators in home collection studies?
CLARIFIED ANSWER: FDA recommends using a high-sensitivity PCR test authorized for home collection as a comparator, along with its associated home collection kit. Saliva specimens and antigen tests are not acceptable comparators.
VERBATIM QUESTION: Which high-sensitivity PCR tests are authorized for use as comparators in home collection studies?
VERBATIM ANSWER: We do recommend a high-sensitivity PCR using a nasal specimen as a comparator. Neither saliva specimens nor antigen tests are acceptable comparators. You should select a high-sensitivity PCR that is authorized for home collection and use the home collection kit with which that selected comparator test is authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Authorized high-sensitivity PCR tests, Comparator tests for home collection studies
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: Does the randomized collection process need to follow specific guidelines beyond alternation of order?
CLARIFIED ANSWER: FDA recommends a gap of 10-15 minutes between the first and second collections to preserve test sensitivity, and prior experience has shown this approach to be effective.
VERBATIM QUESTION: Does the randomized collection process need to follow specific guidelines beyond alternation of order?
VERBATIM ANSWER: We recommend that there is a gap between the first collection and the second collection of probably a minimum of ten to 15 minutes. And when we worked with developers before and have done this, we haven't seen a drop off in sensitivity for either the comparator or the test device.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: randomized collection guidelines, gap between collections
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: What are the criteria for an authorized home collection kit to be suitable for use in this context?
CLARIFIED ANSWER: FDA recommends using a high-sensitivity PCR authorized for home collection with a compatible home collection kit. Saliva specimens and antigen tests are not acceptable.
VERBATIM QUESTION: What are the criteria for an authorized home collection kit to be suitable for use in this context?
VERBATIM ANSWER: We do recommend a high-sensitivity PCR using a nasal specimen as a comparator. Neither saliva specimens nor antigen tests are acceptable comparators. You should select a high-sensitivity PCR that is authorized for home collection and use the home collection kit with which that selected comparator test is authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Criteria for home collection kits, Comparator requirements, Testing protocol
REVIEW FLAG: False

QA Block 2-10
CLARIFIED QUESTION: Are there specific recommendations for ensuring integrity of samples when mailing kits to participants in clinical studies?
CLARIFIED ANSWER: The FDA recommends using a high-sensitivity PCR nasal specimen as a comparator and ensuring that the collection process minimizes bias, such as randomizing the order of tests and sampling both nostrils. Sending a pre-EUA with study details for FDA approval is also suggested.
VERBATIM QUESTION: Are there specific recommendations for ensuring integrity of samples when mailing kits to participants in clinical studies?
VERBATIM ANSWER: Performing the study in a home setting instead of a simulated home environment is potentially acceptable. However we do recommend a high-sensitivity PCR using a nasal specimen as a comparator. Neither saliva specimens nor antigen tests are acceptable comparators. You should select a high-sensitivity PCR that is authorized for home collection and use the home collection kit with which that selected comparator test is authorized. In order to address the concern of which sample is taken first, we recommend that the collection of swabs should be randomized so that the antigen and PCR tests are not consistently drawn in the same order and that both anterior nares should be sampled for each test. We would also recommend that you send in a pre-EUA with your study design and check the comparator selection with FDA prior to initiating your study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Sample integrity, Mailing kits, Clinical study design
REVIEW FLAG: False

QA Block 2-11
CLARIFIED QUESTION: How can developers document and confirm adherence to the recommended collection procedures for swabs?
CLARIFIED ANSWER: Developers should randomize the order of swab collection between antigen and PCR tests and ensure that both anterior nares are sampled for each test.
VERBATIM QUESTION: How can developers document and confirm adherence to the recommended collection procedures for swabs?
VERBATIM ANSWER: In order to address the concern of which sample is taken first, we recommend that the collection of swabs should be randomized so that the antigen and PCR tests are not consistently drawn in the same order and that both anterior nares should be sampled for each test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: swab collection procedures, randomization, nasal sample testing
REVIEW FLAG: False


#### 3. Antigen Test Validation Challenges and NCI Program Clarifications

QA Block 3-1
CLARIFIED QUESTION: What validation studies should test developers conduct for antigen test kits?
CLARIFIED ANSWER: Test developers should independently validate antigen test kits for their intended use population; NCI testing is not available for this purpose.
VERBATIM QUESTION: What validation studies should test developers conduct for antigen test kits?
VERBATIM ANSWER: NCI testing is not currently available for antigen tests and all validations studies should be performed by the test developer to validate the proposed intended use population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation studies, Antigen test kits
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: Is the NCI test evaluation program exclusively for serology tests?
CLARIFIED ANSWER: The NCI test evaluation program is exclusively for serology tests, not for antigen tests. Direct inquiries can be sent to the lead reviewer or the EUA mailbox.
VERBATIM QUESTION: Is the NCI test evaluation program exclusively for serology tests?
VERBATIM ANSWER: The NCI test evaluation program is actually for serology tests. And if you have specific questions about that program, please send them to your lead reviewer if you have one or to that EUA mailbox if you don't yet have a lead reviewer and we're happy to answer those questions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: NCI test evaluation program, serology tests, antigen test validation
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: If antigen test sample banks are challenging to create, what alternatives does FDA recommend?
CLARIFIED ANSWER: The FDA is collaborating with RADx and similar programs to address challenges with antigen test sample banks. Their main focus is to improve evaluation methods for mutation and variant impacts on test performance.
VERBATIM QUESTION: If antigen test sample banks are challenging to create, what alternatives does FDA recommend?
VERBATIM ANSWER: We are working with RADx and other programs to see what we can do. The primary focus right now with these sort of banks is assessing finding better ways to assess the potential impacts of mutations and variance on antigen test performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test sample banks, Mutation/variant impact evaluation, FDA collaborations
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What role does the RADx program play in supporting the development of antigen test validation methods?
CLARIFIED ANSWER: The RADx program is collaborating to develop better methods for assessing how mutations and variants impact antigen test performance.
VERBATIM QUESTION: What role does the RADx program play in supporting the development of antigen test validation methods?
VERBATIM ANSWER: So we are working with RADx and other programs to see what we can do. The primary focus right now with these sort of banks is assessing finding better ways to assess the potential impacts of mutations and variance on antigen test performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RADx program, antigen test validation, mutations and variants
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: How can test developers mitigate challenges associated with antigen tests that do not use VTM?
CLARIFIED ANSWER: FDA acknowledges challenges in creating consistent swab sample banks for antigen tests as they often use direct swabs without VTM. FDA is working with RADx and other programs to address this, focusing on impacts of mutations and variants.
VERBATIM QUESTION: How can test developers mitigate challenges associated with antigen tests that do not use VTM?
VERBATIM ANSWER: The challenge is that direct swabs are usually the sample type here for antigen tests. And, you know, banking those in significant volume where there's consistent - consistency between swabs in a bank is quite challenging. You know, for those tests that use VTM it's a little bit easier to use bank samples. But since most antigen tests don't use VTM in their usual workflow that presents the challenge for having panels for antigens. So we are working with RADx and other programs to see what we can do. The primary focus right now with these sort of banks is assessing finding better ways to assess the potential impacts of mutations and variance on antigen test performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen tests, sample banking, mutations impact
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: What methods can be used to assess the potential impact of mutations and variants on antigen test performance?
CLARIFIED ANSWER: FDA is focusing on using sample banks to find better ways to evaluate the potential impacts of mutations and variants on antigen test performance.
VERBATIM QUESTION: What methods can be used to assess the potential impact of mutations and variants on antigen test performance?
VERBATIM ANSWER: The primary focus right now with these sort of banks is assessing finding better ways to assess the potential impacts of mutations and variance on antigen test performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mutation and variant impact, antigen test performance, sample banks
REVIEW FLAG: False


#### 4. Analytical Testing Guidelines for Antigen Test Validation and EUA Submission

QA Block 4-1
CLARIFIED QUESTION: Can recombinant or purified antigens spiked in negative clinical media be used for analytical performance testing of an antigen test?
CLARIFIED ANSWER: The FDA does not consider recombinant or purified antigens spiked in negative clinical media acceptable for validation as it fails to test the extraction step and does not correlate well with real-world performance.
VERBATIM QUESTION: Can recombinant or purified antigens spiked in negative clinical media be used for analytical performance testing of an antigen test?
VERBATIM ANSWER: No, that we don't consider the use of recombinant or purified antigen to be acceptable for any validation activities. It - since it doesn't test the extraction step of your test. And we found that performance with recombinant or purified antigen does not correlate well with real-world performance.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antigen test validation, analytical performance testing
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Can laboratory-based analytical performance testing, such as stability and limit of detection, be performed outside of the United States?
CLARIFIED ANSWER: Yes, laboratory-based analytical performance testing can be performed outside the United States, but the FDA requires full detailed protocols for each validation study to be included in the EUA submission.
VERBATIM QUESTION: Can laboratory-based analytical performance testing, such as stability and limit of detection, be performed outside of the United States?
VERBATIM ANSWER: Yes. Lab-based analytical testing can be performed outside the US but we do expect to see the full detailed protocols for each validation study as part of the EUA submission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Lab-based analytical testing, Validation protocols, EUA submissions
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Why is the use of recombinant or purified antigens not acceptable for validation activities?
CLARIFIED ANSWER: The FDA does not consider recombinant or purified antigens acceptable for validation activities because they do not test the extraction step and their performance does not correlate well with real-world performance.
VERBATIM QUESTION: Why is the use of recombinant or purified antigens not acceptable for validation activities?
VERBATIM ANSWER: No, that we don't consider the use of recombinant or purified antigen to be acceptable for any validation activities. It - since it doesn't test the extraction step of your test. And we found that performance with recombinant or purified antigen does not correlate well with real-world performance.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation activities, Recombinant/purified antigens, Analytical performance testing
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: What challenges do recombinant or purified antigens present in correlating with real-world performance?
CLARIFIED ANSWER: The FDA does not consider recombinant or purified antigens acceptable for validation activities because they do not test the extraction step and their performance does not correlate well with real-world outcomes.
VERBATIM QUESTION: What challenges do recombinant or purified antigens present in correlating with real-world performance?
VERBATIM ANSWER: No, that we don't consider the use of recombinant or purified antigen to be acceptable for any validation activities. It - since it doesn't test the extraction step of your test. And we found that performance with recombinant or purified antigen does not correlate well with real-world performance.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Recombinant antigen challenges, Validation activities, Real-world performance correlation
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What should developers include in detailed protocols for laboratory-based analytical performance testing conducted outside the US?
CLARIFIED ANSWER: Developers must include full detailed protocols for each validation study as part of the EUA submission when conducting laboratory-based analytical testing outside the US.
VERBATIM QUESTION: What should developers include in detailed protocols for laboratory-based analytical performance testing conducted outside the US?
VERBATIM ANSWER: Lab-based analytical testing can be performed outside the US but we do expect to see the full detailed protocols for each validation study as part of the EUA submission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: analytical performance testing, EUA submission, validation protocols
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: Can recombinant or engineered antigens be used to evaluate the performance of tests with respect to specific mutations or variants?
CLARIFIED ANSWER: The FDA acknowledges that using recombinant or engineered antigens can be useful for monitoring performance related to specific mutations or variants. While they may not be sufficient alone, these could play a role in addressing mutation-related concerns, and the FDA is open to discussions with developers.
VERBATIM QUESTION: Can recombinant or engineered antigens be used to evaluate the performance of tests with respect to specific mutations or variants?
VERBATIM ANSWER: I'll just add something on question one. So absolutely correct what Toby said about authorization decisions. However it may be easier for some developers who want to monitor performance with respect to certain mutations and variants to use engineered antigens, you know, recombinant antigens in particular because they can engineer in the mutation. I'm not sure if that's going to be sufficient only in assessing change and potential performance with mutations, but certainly it's a good thought and we're open to that just, you know, for verifying performance on mutations. So that's one area where recombinant antigen production may be entirely useful in addressing concerns. And we look forward to having conversations with developers on this to make sure that's addressed in any potential concerns the FDA may have.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: use of recombinant antigens, mutation-specific test performance
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: How can developers approach using recombinant antigen production to address potential FDA concerns?
CLARIFIED ANSWER: The FDA is open to developers using recombinant antigens to monitor performance regarding mutations. While its sufficiency is not confirmed, it can be useful for verifying mutation performance. The FDA encourages developers to discuss potential concerns.
VERBATIM QUESTION: How can developers approach using recombinant antigen production to address potential FDA concerns?
VERBATIM ANSWER: I'll just add something on question one. So absolutely correct what Toby said about authorization decisions. However it may be easier for some developers who want to monitor performance with respect to certain mutations and variants to use engineered antigens, you know, recombinant antigens in particular because they can engineer in the mutation. I'm not sure if that's going to be sufficient only in assessing change and potential performance with mutations, but certainly it's a good thought and we're open to that just, you know, for verifying performance on mutations. So that's one area where recombinant antigen production may be entirely useful in addressing concerns. And we look forward to having conversations with developers on this to make sure that's addressed in any potential concerns the FDA may have.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: recombinant antigen use, mutation monitoring, FDA concerns
REVIEW FLAG: False


#### 5. Monitoring Antibody Tests Against SARS-CoV-2 Variants

QA Block 5-1
CLARIFIED QUESTION: How many samples of each SARS-CoV-2 variant are required to be evaluated for monitoring the performance of a lateral flow antibody test?
CLARIFIED ANSWER: FDA does not currently have specific recommendations for the number of SARS-CoV-2 variant-related serology samples required for evaluating test performance. However, EUA requests should include plans for monitoring variants, assessing impacts of prevalent or significant mutations, and mitigating risks from test performance uncertainties. Variant data should include how samples were selected, characterized, and validated.
VERBATIM QUESTION: How many samples of each SARS-CoV-2 variant are required to be evaluated for monitoring the performance of a lateral flow antibody test?
VERBATIM ANSWER: At this time we don't have specific recommendations for the number of SARS CoV-2 variant related serology samples that should be evaluated by wet testing to monitor the performance of SARS CoV-2 serology test. In your EUA request we would like to see your plan for monitoring for a new and emerging SARS CoV-2 viral mutations and variants. And we would expect your plan to include assessing the potential impact of mutations and variance that have been identified as prevalent or clinically significant on the performance of your test. Testing is not expected for every variant that you monitor, but for mutations, the variance that has been identified as prevalent or clinically significant, you should provide information on the potential impact on your test performance considering your specific captured antigen and test technology or explain how the risk associated with the unknown performance of your device in samples from individuals with the variant can be adequately mitigated. And then when variant data is provided we would expect you to describe how the serology samples were selected and characterized and described the sequencing map is used to cross specific variants. That should be included and it should include describing the sequencing method validation such as inclusivity and limited detection and describing the sequence analysis step used to call mutations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Lateral flow antibody test performance, SARS-CoV-2 variants, Testing recommendations
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Is there a specific method required for the confirmation of positive samples in relation to monitoring SARS-CoV-2 variant performance?
CLARIFIED ANSWER: The FDA does not have specific recommendations for the number of serology samples to evaluate SARS-CoV-2 variant performance. EUA submissions should include a monitoring plan for relevant mutations, their potential impacts on test performance, and details on serology sample selection and sequencing methods used.
VERBATIM QUESTION: Is there a specific method required for the confirmation of positive samples in relation to monitoring SARS-CoV-2 variant performance?
VERBATIM ANSWER: At this time we don't have specific recommendations for the number of SARS CoV-2 variant related serology samples that should be evaluated by wet testing to monitor the performance of SARS CoV-2 serology test. In your EUA request we would like to see your plan for monitoring for a new and emerging SARS CoV-2 viral mutations and variants. And we would expect your plan to include assessing the potential impact of mutations and variance that have been identified as prevalent or clinically significant on the performance of your test. Testing is not expected for every variant that you monitor, but for mutations, the variance that has been identified as prevalent or clinically significant, you should provide information on the potential impact on your test performance considering your specific captured antigen and test technology or explain how the risk associated with the unknown performance of your device in samples from individuals with the variant can be adequately mitigated. And then when variant data is provided we would expect you to describe how the serology samples were selected and characterized and described the sequencing map is used to cross specific variants. That should be included and it should include describing the sequencing method validation such as inclusivity and limited detection and describing the sequence analysis step used to call mutations.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 variant monitoring, EUA submission requirements, Testing samples characterization
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What specific elements should a plan for monitoring new and emerging SARS-CoV-2 viral mutations and variants include in an EUA request?
CLARIFIED ANSWER: The FDA expects EUA requests to include a plan that assesses the impact of prevalent or clinically significant SARS-CoV-2 mutations and variants on test performance, provides information on mitigations for unknown performance risks, and describes how samples were selected, characterized, and analyzed, including sequencing validations like inclusivity and detection limits.
VERBATIM QUESTION: What specific elements should a plan for monitoring new and emerging SARS-CoV-2 viral mutations and variants include in an EUA request?
VERBATIM ANSWER: In your EUA request we would like to see your plan for monitoring for a new and emerging SARS CoV-2 viral mutations and variants. And we would expect your plan to include assessing the potential impact of mutations and variance that have been identified as prevalent or clinically significant on the performance of your test. Testing is not expected for every variant that you monitor, but for mutations, the variance that has been identified as prevalent or clinically significant, you should provide information on the potential impact on your test performance considering your specific captured antigen and test technology or explain how the risk associated with the unknown performance of your device in samples from individuals with the variant can be adequately mitigated. And then when variant data is provided we would expect you to describe how the serology samples were selected and characterized and described the sequencing map is used to cross specific variants. That should be included and it should include describing the sequencing method validation such as inclusivity and limited detection and describing the sequence analysis step used to call mutations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA request requirements, SARS-CoV-2 mutations and variants, Test performance monitoring
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: How should developers assess the potential impact of identified prevalent or clinically significant variants on the performance of their tests?
CLARIFIED ANSWER: Developers should submit a monitoring plan as part of their EUA request, including an assessment of the impact of prevalent or significant mutations on test performance or an explanation of how risks related to unknown performance are mitigated.
VERBATIM QUESTION: How should developers assess the potential impact of identified prevalent or clinically significant variants on the performance of their tests?
VERBATIM ANSWER: In your EUA request we would like to see your plan for monitoring for a new and emerging SARS CoV-2 viral mutations and variants. And we would expect your plan to include assessing the potential impact of mutations and variance that have been identified as prevalent or clinically significant on the performance of your test. Testing is not expected for every variant that you monitor, but for mutations, the variance that has been identified as prevalent or clinically significant, you should provide information on the potential impact on your test performance considering your specific captured antigen and test technology or explain how the risk associated with the unknown performance of your device in samples from individuals with the variant can be adequately mitigated.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission, Variant impact assessment, Mitigation plans
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: What information should be provided to mitigate the risk of unknown performance in samples from individuals with prevalent variants?
CLARIFIED ANSWER: FDA recommends including in your EUA submission a plan to monitor for emerging mutations and variants, assessing their impact on test performance, and providing details on how risks from unknown performance against prevalent variants are mitigated. Include characterization and sequencing method validation for variant data.
VERBATIM QUESTION: What information should be provided to mitigate the risk of unknown performance in samples from individuals with prevalent variants?
VERBATIM ANSWER: In your EUA request we would like to see your plan for monitoring for a new and emerging SARS CoV-2 viral mutations and variants. And we would expect your plan to include assessing the potential impact of mutations and variance that have been identified as prevalent or clinically significant on the performance of your test. Testing is not expected for every variant that you monitor, but for mutations, the variance that has been identified as prevalent or clinically significant, you should provide information on the potential impact on your test performance considering your specific captured antigen and test technology or explain how the risk associated with the unknown performance of your device in samples from individuals with the variant can be adequately mitigated. And then when variant data is provided we would expect you to describe how the serology samples were selected and characterized and described the sequencing map is used to cross specific variants. That should be included and it should include describing the sequencing method validation such as inclusivity and limited detection and describing the sequence analysis step used to call mutations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission requirements, Mitigating unknown test performance, Variant impact assessment
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: What details should be included when describing how serology samples were selected and characterized for variant evaluation?
CLARIFIED ANSWER: When providing variant data, include details on how serology samples were selected and characterized, describe sequencing maps used to identify specific variants, validate sequencing methods (e.g., inclusivity, limit of detection), and describe sequence analysis steps used to call mutations.
VERBATIM QUESTION: What details should be included when describing how serology samples were selected and characterized for variant evaluation?
VERBATIM ANSWER: And then when variant data is provided we would expect you to describe how the serology samples were selected and characterized and described the sequencing map is used to cross specific variants. That should be included and it should include describing the sequencing method validation such as inclusivity and limited detection and describing the sequence analysis step used to call mutations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serology sample characterization, Sequencing method validation, Variant evaluation
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: What sequencing method validation details, such as inclusivity and limit of detection, should be included when submitting variant data?
CLARIFIED ANSWER: FDA expects submissions of variant data to describe how serology samples were selected and characterized, include sequencing method validation (e.g., inclusivity and limit of detection), and detail the sequence analysis steps used to call mutations.
VERBATIM QUESTION: What sequencing method validation details, such as inclusivity and limit of detection, should be included when submitting variant data?
VERBATIM ANSWER: And then when variant data is provided we would expect you to describe how the serology samples were selected and characterized and described the sequencing map is used to cross specific variants. That should be included and it should include describing the sequencing method validation such as inclusivity and limited detection and describing the sequence analysis step used to call mutations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: sequencing method validation, inclusivity and limit of detection, variant data requirements
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: How should developers describe the sequence analysis steps used to identify mutations in their submissions?
CLARIFIED ANSWER: Developers should describe how serology samples were selected and characterized, including the sequencing method validation such as inclusivity, limit of detection, and steps used to identify mutations.
VERBATIM QUESTION: How should developers describe the sequence analysis steps used to identify mutations in their submissions?
VERBATIM ANSWER: And then when variant data is provided we would expect you to describe how the serology samples were selected and characterized and described the sequencing map is used to cross specific variants. That should be included and it should include describing the sequencing method validation such as inclusivity and limited detection and describing the sequence analysis step used to call mutations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: sequence analysis, mutation identification, EUA submissions
REVIEW FLAG: False


#### 6. FDA Guidance on Antigen Test Mutations and Study Requirements

QA Block 6-1
CLARIFIED QUESTION: Is FDA going to be updating the antigen test template because of the development of mutations 1051 and D399N, even though their prevalence appears to be very low?
CLARIFIED ANSWER: FDA will not update the antigen test template for mutation D399N due to its very low prevalence in the U.S. (below 1%). Updates are made only if mutations significantly impact test performance or reach a high prevalence threshold.
VERBATIM QUESTION: Is FDA going to be updating the antigen test template because of the development of mutations 1051 and D399N, even though their prevalence appears to be very low?
VERBATIM ANSWER: I'm not familiar with the T2051 so off the top of my head but I'll look into it. But the 399N it is in very low prevalence in the United States right now, well below 1%. And so and we know that - we know about the report that Sofia SARS and any of the Sofia SARS tests may not detect this mutation. But because it's in so low abundance it does not reach - if in fact it is confirmed that Sofia test doesn't detect the 399N, you know, we won't be updating the Web site because we're reserving updating the Web site where we think that the prevalence of certain mutations that could impact performance is high enough that it warrants a Web site update. So we're really looking at either individual mutations or a combination of mutation for antigen tests that would drop performance by 5% or more same goes for molecular tests. And so we do have guidance on the what developers should do regarding variants and we are very active in monitoring the variants obviously in talking to developers. And when it becomes important to make that information publicly available, in our Web site we'll post the information there.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test updates, Mutation D399N, Test performance monitoring
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Does FDA expect that a lab conducting analytical work outside the US should be GLP or would ISO 17025 be acceptable?
CLARIFIED ANSWER: FDA does not have a specific laboratory standard requirement for analytical studies under EUAs. They suggest properly designing and documenting studies to ensure effectiveness.
VERBATIM QUESTION: Does FDA expect that a lab conducting analytical work outside the US should be GLP or would ISO 17025 be acceptable?
VERBATIM ANSWER: We do waive for EUAs and much of QS are regulations, and that's spelled out in the letter of authorization. So while we always love it when developers even for EUAs do it fully within QSR compliant facilities and methods and everything, we are more flexible. So I don't believe and Toby correct me, I don't believe we have a specific laboratory requirement. We do recommend that, you know, you properly design your analytical studies and you form your study plans and document it before starting the studies and, you know, because we will want to see those study designs for that, the studies and for their appropriateness and then so that we can measure the effectiveness.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Laboratory requirements, Analytical studies under EUA
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: How many matrices are expected to be tested for a nasal swab antigen test for at-home use, as it is unclear in Part J Part 1 of the template?
CLARIFIED ANSWER: FDA requires only one sample matrix that demonstrates adequate performance for nasal swab antigen tests. Additional testing is up to the developer.
VERBATIM QUESTION: How many matrices are expected to be tested for a nasal swab antigen test for at-home use, as it is unclear in Part J Part 1 of the template?
VERBATIM ANSWER: And the third question I think had to do a different sample matrices that we recommend for a test and test developers. We really only need one that works, right? So if analytical, if anterior nares sampling, bilateral nares samples gives you an adequate performance to meet our recommended levels, you know, that's sufficient. And then it's really up to the developer or they want to do more. And it could be an MP swab, could be a mid-turbinate swab, you know, for antigen test. But it's really what the developer wants part of the acceptable sample type and properly validated enabled unintelligible.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample matrices, nasal swab antigen tests, validation requirements
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: What is the threshold of mutation prevalence that requires the FDA to update its guidance or website?
CLARIFIED ANSWER: The FDA updates guidance or its website when the prevalence of mutations significantly impacts test performance, specifically when it causes a 5% or more drop in performance for either antigen or molecular tests.
VERBATIM QUESTION: What is the threshold of mutation prevalence that requires the FDA to update its guidance or website?
VERBATIM ANSWER: But the 399N it is in very low prevalence in the United States right now, well below 1%. And so and we know that - we know about the report that Sofia SARS and any of the Sofia SARS tests may not detect this mutation. But because it's in so low abundance it does not reach - if in fact it is confirmed that Sofia test doesn't detect the 399N, you know, we won't be updating the Web site because we're reserving updating the Web site where we think that the prevalence of certain mutations that could impact performance is high enough that it warrants a Web site update. So we're really looking at either individual mutations or a combination of mutation for antigen tests that would drop performance by 5% or more same goes for molecular tests. And so we do have guidance on the what developers should do regarding variants and we are very active in monitoring the variants obviously in talking to developers. And when it becomes important to make that information publicly available, in our Web site we'll post the information there.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Threshold for mutation prevalence, Website update criteria, Performance impact
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: How does the FDA define a significant drop in test performance (e.g., 5%) due to mutations?
CLARIFIED ANSWER: The FDA defines a significant drop in test performance as a reduction of 5% or more due to mutations, applicable to both antigen and molecular tests. The FDA actively monitors variants and provides guidance to developers, updating the public through their website when necessary.
VERBATIM QUESTION: How does the FDA define a significant drop in test performance (e.g., 5%) due to mutations?
VERBATIM ANSWER: So we're really looking at either individual mutations or a combination of mutation for antigen tests that would drop performance by 5% or more same goes for molecular tests. And so we do have guidance on the what developers should do regarding variants and we are very active in monitoring the variants obviously in talking to developers. And when it becomes important to make that information publicly available, in our Web site we'll post the information there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test performance threshold, Mutations impact, FDA guidance
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: What steps should developers take if their antigen or molecular test is suspected to be affected by a low-prevalence mutation?
CLARIFIED ANSWER: The FDA has guidelines for developers on managing variants and actively monitors and engages with developers. Relevant updates are posted on the FDA website as needed.
VERBATIM QUESTION: What steps should developers take if their antigen or molecular test is suspected to be affected by a low-prevalence mutation?
VERBATIM ANSWER: And so we do have guidance on the what developers should do regarding variants and we are very active in monitoring the variants obviously in talking to developers. And when it becomes important to make that information publicly available, in our Web site we'll post the information there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Low-prevalence mutation, Antigen and molecular test updates, FDA monitoring
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: Does the FDA provide detailed guidance on study plan formats for analytical studies?
CLARIFIED ANSWER: The FDA recommends that developers properly design, document, and form study plans before starting analytical studies, as the agency reviews these for appropriateness and effectiveness.
VERBATIM QUESTION: Does the FDA provide detailed guidance on study plan formats for analytical studies?
VERBATIM ANSWER: We do recommend that, you know, you properly design your analytical studies and you form your study plans and document it before starting the studies and, you know, because we will want to see those study designs for that, the studies and for their appropriateness and then so that we can measure the effectiveness.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Analytical study plan guidance, Documentation requirements for studies
REVIEW FLAG: False

QA Block 6-8
CLARIFIED QUESTION: Are there any specific criteria for documenting study designs for EUA submissions?
CLARIFIED ANSWER: The FDA does not mandate a specific laboratory requirement for EUAs but encourages developers to properly design, plan, and document their analytical studies before beginning, as study designs will be reviewed for appropriateness and effectiveness.
VERBATIM QUESTION: Are there any specific criteria for documenting study designs for EUA submissions?
VERBATIM ANSWER: We do waive for EUAs and much of QS are regulations, and that's spelled out in the letter of authorization. So while we always love it when developers even for EUAs do it fully within QSR compliant facilities and methods and everything, we are more flexible. So I don't believe and Toby correct me, I don't believe we have a specific laboratory requirement. We do recommend that, you know, you properly design your analytical studies and you form your study plans and document it before starting the studies and, you know, because we will want to see those study designs for that, the studies and for their appropriateness and then so that we can measure the effectiveness.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA study documentation, FDA criteria, Analytical study requirements
REVIEW FLAG: False

QA Block 6-9
CLARIFIED QUESTION: Can developers validate additional sample types even if initial performance requirements are met with one sample matrix?
CLARIFIED ANSWER: The FDA requires only one validated sample type to meet performance requirements. Developers can choose to validate additional types if desired.
VERBATIM QUESTION: Can developers validate additional sample types even if initial performance requirements are met with one sample matrix?
VERBATIM ANSWER: And the third question I think had to do a different sample matrices that we recommend for a test and test developers. We really only need one that works, right? So if analytical, if anterior nares sampling, bilateral nares samples gives you an adequate performance to meet our recommended levels, you know, that's sufficient. And then it's really up to the developer or they want to do more. And it could be an MP swab, could be a mid-turbinate swab, you know, for antigen test. But it's really what the developer wants part of the acceptable sample type and properly validated enabled unintelligible.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sample matrix validation, FDA performance requirements, Test development flexibility
REVIEW FLAG: False

QA Block 6-10
CLARIFIED QUESTION: Is there flexibility in using different sample matrices provided they are properly validated?
CLARIFIED ANSWER: FDA allows flexibility in the choice of sample matrices for tests, provided the selected type meets performance requirements and is properly validated.
VERBATIM QUESTION: Is there flexibility in using different sample matrices provided they are properly validated?
VERBATIM ANSWER: And the third question I think had to do a different sample matrices that we recommend for a test and test developers. We really only need one that works, right? So if analytical, if anterior nares sampling, bilateral nares samples gives you an adequate performance to meet our recommended levels, you know, that's sufficient. And then it's really up to the developer or they want to do more. And it could be an MP swab, could be a mid-turbinate swab, you know, for antigen test. But it's really what the developer wants part of the acceptable sample type and properly validated enabled unintelligible.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sample matrices, Validation flexibility, Test development
REVIEW FLAG: False


#### 7. Challenges in Validating Saliva Antigen Tests

QA Block 7-2
CLARIFIED QUESTION: Can artificial saliva, fresh saliva, or commercially sourced saliva be used as the clinical matrix for a saliva antigen test?
CLARIFIED ANSWER: FDA advises submitting a pre-EUA for saliva antigen tests and does not currently permit completely artificial samples. Banked or contrived samples are generally acceptable for analytical studies, but saliva as a sample type for antigen tests is challenging. No saliva-based antigen test has been authorized yet.
VERBATIM QUESTION: Can artificial saliva, fresh saliva, or commercially sourced saliva be used as the clinical matrix for a saliva antigen test?
VERBATIM ANSWER: You know, I recommend submitting a pre-EUA for your saliva antigen test and your plans. Typically we won't allow, you know, completely artificial samples for anything right now including saliva. And the use of banked samples especially for analytical study is fine. The use of contrived samples is generally okay for analytical studies meaning you take a negative patient saliva or pooled saliva and you spike in virus, whole virus inactivated will work. Or you can dilute a positive patient saliva sample into a negative pool in order to get the dilutions that you, you know, would want for your analytical studies. But again we don't have recommendations out there on validation of saliva antigen tests. We do think that's a particularly challenging sample type for antigen tests. There's growing body of information that it is submitting less sometimes for saliva amount of virus. By, you know, we're open to it. We're not saying don't do it. It's just I don't believe we've authorized one yet. And we haven't yet obviously then received an application for a saliva based antigen test that we could authorize.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva antigen tests, sample validation, pre-EUA submissions
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: For the clinical evaluation, is it acceptable to use banked samples if it is difficult to obtain enough positive samples for antigen tests?
CLARIFIED ANSWER: The FDA does not generally recommend using banked samples for antigen tests as the freeze-thaw process artificially increases sensitivity, complicating real-world performance evaluation. Submitting a pre-EUA is encouraged for flexibility requests.
VERBATIM QUESTION: For the clinical evaluation, is it acceptable to use banked samples if it is difficult to obtain enough positive samples for antigen tests?
VERBATIM ANSWER: Antigen tests are more challenging because we've observed that the freeze-thaw process seems to increase access shall we say to the antigen. And it's an artificial increase in assay sensitivity that is hard to control and understand. And we really want to understand real-world performance. So, you know, anything that doesn't follow sort of, you know, an, you know, our sort of standard recommendations for antigen tests, again I do recommend that you submit a pre-EUA and ask for any, you know, flexibility that you need to develop your test. But molecular is a little bit different because they typically have an extraction step and, you know, for those essays that - although we do examine about whether freeze-thaw does impact molecular as well so we do ask for freestyle studies. But with antigen it's been pretty consistent that the sensitivity increases with the freeze-thaw cycle.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test evaluation, Banked sample limitations, Freeze-thaw impact
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: What are the FDA's general expectations for submitting a pre-EUA for saliva-based antigen tests?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA for saliva antigen tests, outlining plans and study details. Artificial samples are not allowed, though contrived and banked samples may be acceptable for analytical studies. Saliva poses challenges for antigen detection and no saliva-based antigen test has been authorized yet.
VERBATIM QUESTION: What are the FDA's general expectations for submitting a pre-EUA for saliva-based antigen tests?
VERBATIM ANSWER: You know, I recommend submitting a pre-EUA for your saliva antigen test and your plans. Typically we won't allow, you know, completely artificial samples for anything right now including saliva. And the use of banked samples especially for analytical study is fine. The use of contrived samples is generally okay for analytical studies meaning you take a negative patient saliva or pooled saliva and you spike in virus, whole virus inactivated will work. Or you can dilute a positive patient saliva sample into a negative pool in order to get the dilutions that you, you know, would want for your analytical studies. But again we don't have recommendations out there on validation of saliva antigen tests. We do think that's a particularly challenging sample type for antigen tests. There's growing body of information that it is submitting less sometimes for saliva amount of virus. By, you know, we're open to it. We're not saying don't do it. It's just I don't believe we've authorized one yet. And we haven't yet obviously then received an application for a saliva based antigen test that we could authorize.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva antigen tests, Pre-EUA submission, Sample types
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: Are contrived samples acceptable for analytical studies involving saliva-based tests?
CLARIFIED ANSWER: FDA permits the use of contrived samples for analytical studies. These include taking negative patient saliva or pooled saliva, spiking it with inactivated whole virus, or diluting positive patient saliva into a negative pool to achieve desired dilutions.
VERBATIM QUESTION: Are contrived samples acceptable for analytical studies involving saliva-based tests?
VERBATIM ANSWER: The use of contrived samples is generally okay for analytical studies meaning you take a negative patient saliva or pooled saliva and you spike in virus, whole virus inactivated will work. Or you can dilute a positive patient saliva sample into a negative pool in order to get the dilutions that you, you know, would want for your analytical studies.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: contrived samples, saliva-based tests, analytical studies
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Does the FDA have specific recommendations for validating saliva antigen tests, given their challenging nature?
CLARIFIED ANSWER: The FDA does not yet have specific recommendations for validating saliva antigen tests as they are a particularly challenging sample type. They recommend submitting a pre-EUA for such tests and shared that contrived samples and banked samples are generally acceptable for analytical studies. However, no saliva-based antigen test has been authorized yet.
VERBATIM QUESTION: Does the FDA have specific recommendations for validating saliva antigen tests, given their challenging nature?
VERBATIM ANSWER: I recommend submitting a pre-EUA for your saliva antigen test and your plans. Typically we won't allow, you know, completely artificial samples for anything right now including saliva. And the use of banked samples especially for analytical study is fine. The use of contrived samples is generally okay for analytical studies meaning you take a negative patient saliva or pooled saliva and you spike in virus, whole virus inactivated will work. Or you can dilute a positive patient saliva sample into a negative pool in order to get the dilutions that you, you know, would want for your analytical studies. But again we don't have recommendations out there on validation of saliva antigen tests. We do think that's a particularly challenging sample type for antigen tests. There's growing body of information that it is submitting less sometimes for saliva amount of virus. By, you know, we're open to it. We're not saying don't do it. It's just I don't believe we've authorized one yet. And we haven't yet obviously then received an application for a saliva based antigen test that we could authorize.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva antigen test validation, FDA recommendations, Sample type challenges
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: What is the threshold for the amount of virus in saliva needed for effective antigen testing?
CLARIFIED ANSWER: FDA notes that saliva amounts in antigen testing may sometimes have reduced virus levels. While the FDA is open to evaluating such tests, none have been authorized so far or submitted for authorization.
VERBATIM QUESTION: What is the threshold for the amount of virus in saliva needed for effective antigen testing?
VERBATIM ANSWER: There's growing body of information that it is submitting less sometimes for saliva amount of virus. By, you know, we're open to it. We're not saying don't do it. It's just I don't believe we've authorized one yet. And we haven't yet obviously then received an application for a saliva based antigen test that we could authorize.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen testing, saliva virus levels, test authorization
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: How does the freeze-thaw process impact the sensitivity of antigen-based tests compared to molecular tests?
CLARIFIED ANSWER: The sensitivity of antigen tests artificially increases with the freeze-thaw process, which complicates real-world performance evaluation. Molecular tests are less affected due to their extraction step, but freeze-thaw studies are still required for them as well.
VERBATIM QUESTION: How does the freeze-thaw process impact the sensitivity of antigen-based tests compared to molecular tests?
VERBATIM ANSWER: Antigen tests are more challenging because we've observed that the freeze-thaw process seems to increase access shall we say to the antigen. And it's an artificial increase in assay sensitivity that is hard to control and understand. And we really want to understand real-world performance. So, you know, anything that doesn't follow sort of, you know, an, you know, our sort of standard recommendations for antigen tests, again I do recommend that you submit a pre-EUA and ask for any, you know, flexibility that you need to develop your test. But molecular is a little bit different because they typically have an extraction step and, you know, for those essays that - although we do examine about whether freeze-thaw does impact molecular as well so we do ask for freestyle studies. But with antigen it's been pretty consistent that the sensitivity increases with the freeze-thaw cycle.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Freeze-thaw impact, Antigen test sensitivity, Molecular tests
REVIEW FLAG: False

QA Block 7-9
CLARIFIED QUESTION: What flexibility can be requested in a pre-EUA submission for antigen tests that do not align with standard FDA recommendations?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA for any antigen test that does not align with their standard recommendations, allowing developers to request needed flexibilities.
VERBATIM QUESTION: What flexibility can be requested in a pre-EUA submission for antigen tests that do not align with standard FDA recommendations?
VERBATIM ANSWER: Antigen tests are more challenging because we've observed that the freeze-thaw process seems to increase access shall we say to the antigen. And it's an artificial increase in assay sensitivity that is hard to control and understand. And we really want to understand real-world performance. So, you know, anything that doesn't follow sort of, you know, an, you know, our sort of standard recommendations for antigen tests, again I do recommend that you submit a pre-EUA and ask for any, you know, flexibility that you need to develop your test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test flexibility, pre-EUA submission
REVIEW FLAG: False


#### 8. Delays in COVID Test Decision Summary Publication

QA Block 8-2
CLARIFIED QUESTION: Will the decision summary for the BioFire de novo assay definitely be made available?
CLARIFIED ANSWER: The FDA cannot predict when the decision summary for the BioFire de novo assay will be available. It must first go through a process to assess proprietary information, which is beyond FDA's control.
VERBATIM QUESTION: You mentioned in several of the meetings of the desire to move towards full approval for COVID tests. And the only one that you've approved is the de novo from BioFire. And it would be most helpful I would think for developers to see the decision summary for that assay which is still not available according to the database. So I'm wondering if you could shed any light on when and if that decision summary will be made available?
VERBATIM ANSWER: Yes I mean Toby will know the exact protocol for these to get posted, but it goes through a process of looking for any proprietary information that about the assay that we authorized that shouldn't be disclosed publicly. So it leaves our office and it's go through this process and we're not entirely in control of it and we can't, just like guidance, we can't predict when it's going to come out. However for those developers for molecular serology and antigen tests that want to pursue full authorization, as I said we're accepting Pre-Subs for COVID related applications. And as soon as we can post that that decision, we will.
SPEAKER QUESTION: Don Caffiter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: BioFire de novo assay, decision summary timeline, FDA process
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: What is the protocol for reviewing proprietary information before posting decision summaries?
CLARIFIED ANSWER: The FDA reviews proprietary information of an authorized assay to ensure it is not disclosed publicly before the decision summary is posted. However, the timing is not entirely under FDA's control.
VERBATIM QUESTION: What is the protocol for reviewing proprietary information before posting decision summaries?
VERBATIM ANSWER: Yes I mean Toby will know the exact protocol for these to get posted, but it goes through a process of looking for any proprietary information that about the assay that we authorized that shouldn't be disclosed publicly. So it leaves our office and it's go through this process and we're not entirely in control of it and we can't, just like guidance, we can't predict when it's going to come out.
SPEAKER QUESTION: Don Caffiter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: proprietary information review, COVID test decision summaries
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: How can developers utilize the Pre-Sub process for achieving full authorization of COVID-19 diagnostic tests?
CLARIFIED ANSWER: Developers seeking full authorization for molecular serology and antigen tests can submit Pre-Subs for COVID-19 related applications.
VERBATIM QUESTION: How can developers utilize the Pre-Sub process for achieving full authorization of COVID-19 diagnostic tests?
VERBATIM ANSWER: However for those developers for molecular serology and antigen tests that want to pursue full authorization, as I said we're accepting Pre-Subs for COVID related applications.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-Sub process, COVID-19 test authorization
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: What steps is the FDA taking to expedite the posting of decision summaries for authorized COVID-19 tests?
CLARIFIED ANSWER: The FDA is working to expedite the posting of decision summaries, but the process involves steps outside their full control and is not very fast.
VERBATIM QUESTION: What steps is the FDA taking to expedite the posting of decision summaries for authorized COVID-19 tests?
VERBATIM ANSWER: Yes we have been working to expedite posting of that. It has hit some - you know, it does need to go through a unintelligible process and it is unfortunately not the fastest process in the world but we are working to expedite it because we do need to know how valuable that would be for developers to have access to.
SPEAKER QUESTION: Don Caffiter
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Expediting posting of decision summaries, Process delays, Support for developers
REVIEW FLAG: False


#### 9. Standards for Bio-Specimens in Diagnostic Test Validation

QA Block 9-1
CLARIFIED QUESTION: Can you restate the CDRH position on what is acceptable for a bio-repository test versus a live specimen for molecular and antibody tests?
CLARIFIED ANSWER: For central lab and high complexity tests, frozen samples are largely acceptable if freeze-thaw studies show no adverse effects. For point-of-care or home tests, using banked samples poses challenges and should go through processes like pre-EUA to address potential biases.
VERBATIM QUESTION: Can you restate the CDRH position on what is acceptable for a bio-repository test versus a live specimen for molecular and antibody tests?
VERBATIM ANSWER: I think we for central lab tests and moderate and high complexity labs test authorization, frozen samples are largely acceptable for that. We'll want to see freeze-thaw studies to make sure that they behave the same, you know, seeing in paired samples. When you move into point-of-care or home situations that's where it gets a little bit more tricky. I don't know if our current templates spell out the use of banked samples, but we always do recommend that if you're going to use bank samples for your analytical and/or clinical studies that you do check through the pre-EUA process and if you're going for full authorization through the precept process to make sure that your design of studies using bank samples, you know, mitigates completely or to the extent it can be any sort of bias.
SPEAKER QUESTION: Richard Darren
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: bio-repository vs live specimens, molecular and serology tests, FDA study recommendations
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: Would the sensitivity minimum limits be different for a home use or point-of-care test versus a centralized laboratory test?
CLARIFIED ANSWER: Yes, sensitivity minimum limits differ for home use or point-of-care tests versus centralized lab tests. For molecular and serology tests, templates specify requirements. For point-of-care and home molecular tests, 80% PPA is the recommended minimum. FDA evaluates thresholds based on specific applications and templates outline these details.
VERBATIM QUESTION: With regard to a home use test would the sensitivity minimum limits be different in for the home use or point-of-care test versus a centralized laboratory test?
VERBATIM ANSWER: Yes clinical sensitivity or positive percent agreement to a comparator or to the, you know, the test of record, you know, for molecular and serology they would be different answers for that. I think we have - well I know that the home template for antigen molecular spells this out. And then I think we have a home collection template for serology. So you should be able to get a good idea. Basically for serology testing we're really sort of have set levels of sensitivity or PPA recommendations as well as specificity or MPA. For - and for home - and for point of care molecular it's 80% is the floor that we recommend. We really like to see good concordance to central and molecular tests for all molecular tests whether they be in-home or point-of-care. But we will authorize molecular tests between 80% and 95% PPA compared to a high sensitivity central molecular tests. And the same thing for home molecular tests. And then there are various thresholds for different applications such as if you want OTC and there's different pathways for the OTC. And those are all laid out fairly clearly in our templates so I'm not going to go over those again right now.
SPEAKER QUESTION: Richard Darren
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sensitivity limits, Home use tests, Point-of-care tests
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What are the requirements for conducting freeze-thaw studies on frozen samples to ensure accurate results?
CLARIFIED ANSWER: The FDA requires freeze-thaw studies to ensure frozen samples behave the same as live samples, particularly through analysis of paired samples, for central lab tests and high-complexity test authorizations.
VERBATIM QUESTION: What are the requirements for conducting freeze-thaw studies on frozen samples to ensure accurate results?
VERBATIM ANSWER: I think we for central lab tests and moderate and high complexity labs test authorization, frozen samples are largely acceptable for that. We'll want to see freeze-thaw studies to make sure that they behave the same, you know, seeing in paired samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: freeze-thaw study requirements, frozen sample validation, lab test authorization
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: For point-of-care or home use tests, what additional considerations are necessary when using banked samples instead of live specimens?
CLARIFIED ANSWER: For point-of-care or home use tests, the FDA advises consulting through the pre-EUA or pre-authorization process to ensure that study designs using banked samples sufficiently mitigate possible bias.
VERBATIM QUESTION: For point-of-care or home use tests, what additional considerations are necessary when using banked samples instead of live specimens?
VERBATIM ANSWER: When you move into point-of-care or home situations that's where it gets a little bit more tricky. I don't know if our current templates spell out the use of banked samples, but we always do recommend that if you're going to use bank samples for your analytical and/or clinical studies that you do check through the pre-EUA process and if you're going for full authorization through the precept process to make sure that your design of studies using bank samples, you know, mitigates completely or to the extent it can be any sort of bias.
SPEAKER QUESTION: Richard Darren
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: banked vs live samples, point-of-care testing, home use diagnostics
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: Does the FDA provide specific guidance for designing studies that mitigate bias when using banked samples for analytical or clinical studies?
CLARIFIED ANSWER: The FDA advises checking through the pre-EUA and pre-submission processes to ensure study designs using banked samples mitigate bias for analytical or clinical studies.
VERBATIM QUESTION: Does the FDA provide specific guidance for designing studies that mitigate bias when using banked samples for analytical or clinical studies?
VERBATIM ANSWER: I think we for central lab tests and moderate and high complexity labs test authorization, frozen samples are largely acceptable for that. We'll want to see freeze-thaw studies to make sure that they behave the same, you know, seeing in paired samples. When you move into point-of-care or home situations that's where it gets a little bit more tricky. I don't know if our current templates spell out the use of banked samples, but we always do recommend that if you're going to use bank samples for your analytical and/or clinical studies that you do check through the pre-EUA process and if you're going for full authorization through the precept process to make sure that your design of studies using bank samples, you know, mitigates completely or to the extent it can be any sort of bias.
SPEAKER QUESTION: Richard Darren
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: banked sample guidance, bias mitigation, FDA study recommendations
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: What are the thresholds or guidelines for over-the-counter (OTC) home molecular testing pathways?
CLARIFIED ANSWER: The thresholds and pathways for OTC home molecular testing are detailed in FDA templates.
VERBATIM QUESTION: What are the thresholds or guidelines for over-the-counter (OTC) home molecular testing pathways?
VERBATIM ANSWER: And then there are various thresholds for different applications such as if you want OTC and there's different pathways for the OTC. And those are all laid out fairly clearly in our templates so I'm not going to go over those again right now.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC home molecular testing, testing thresholds, FDA templates
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: Does FDA have templates that provide detailed recommendations for using banked specimens in test validation?
CLARIFIED ANSWER: The FDA is unsure if its templates provide detailed recommendations for using banked samples but advises consulting the pre-EUA or pre-submission process when using banked samples in test validation to address potential biases.
VERBATIM QUESTION: Does FDA have templates that provide detailed recommendations for using banked specimens in test validation?
VERBATIM ANSWER: I don't know if our current templates spell out the use of banked samples, but we always do recommend that if you're going to use bank samples for your analytical and/or clinical studies that you do check through the pre-EUA process and if you're going for full authorization through the precept process to make sure that your design of studies using bank samples, you know, mitigates completely or to the extent it can be any sort of bias.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: banked samples, FDA templates, test validation
REVIEW FLAG: False


#### 10. Prioritizing High Throughput Tests for Asymptomatic Screening

QA Block 10-1
CLARIFIED QUESTION: Does the FDA priority for asymptomatic amendments also extend to new submissions for asymptomatic testing?
CLARIFIED ANSWER: The FDA prioritizes high-throughput asymptomatic screening tests. New submissions that do not meet prioritization criteria, such as high throughput and point-of-care access, will not be prioritized but can pursue the regular authorization pathway.
VERBATIM QUESTION: Does the FDA priority for asymptomatic amendments also extend to new submissions for asymptomatic testing?
VERBATIM ANSWER: Yes with the central lab test we are also asking for, you know, it be a high throughput test. So a low-throughput test isn't really going to advance our capability as a country to address the huge numbers of tests that are needed for asymptomatically screening our population. And we're really driving development priorities towards those extremely high throughput tests. And those are the ones that we're prioritizing so simply a new submission, you know, adding asymptomatic screening that doesn't also meet our access. Our access is point-of-care in-home. But if it's a central - if it's moderate to high complexity test and it doesn't have - and it doesn't meet the throughput template it's not going to be prioritized right now and it probably won't be going forward. The regular full authorization pathway it is open to test developers who don't meet our pandemic priorities, you know, which are probably going to be, you know, pretty similar going forward. And so that pathway is open to them. We are accepting MDUFA applications as I said at the beginning of the call and we're not putting them on hold. They may take a little bit longer than we'd like and the same thing goes for pre-submissions.
SPEAKER QUESTION: Josh Profeto
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA priority for asymptomatic testing, Submission pathways, High-throughput vs low-throughput criteria
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: If we resubmit a new EUA now with asymptomatic validation, would that be a higher priority?
CLARIFIED ANSWER: The FDA is prioritizing high-throughput tests for asymptomatic screening. If a new submission does not meet the throughput standard or pandemic priorities, it will not receive high priority. However, submissions can still follow the regular authorization process.
VERBATIM QUESTION: If we resubmit a new EUA now with asymptomatic validation, would that be a higher priority?
VERBATIM ANSWER: Yes with the central lab test we are also asking for, you know, it be a high throughput test. So a low-throughput test isn't really going to advance our capability as a country to address the huge numbers of tests that are needed for asymptomatically screening our population. And we're really driving development priorities towards those extremely high throughput tests. And those are the ones that we're prioritizing so simply a new submission, you know, adding asymptomatic screening that doesn't also meet our access. Our access is point-of-care in-home. But if it's a central - if it's moderate to high complexity test and it doesn't have - and it doesn't meet the throughput template it's not going to be prioritized right now and it probably won't be going forward. The regular full authorization pathway it is open to test developers who don't meet our pandemic priorities, you know, which are probably going to be, you know, pretty similar going forward. And so that pathway is open to them. We are accepting MDUFA applications as I said at the beginning of the call and we're not putting them on hold. They may take a little bit longer than we'd like and the same thing goes for pre-submissions.
SPEAKER QUESTION: Josh Profeto
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA resubmission, asymptomatic screening, FDA test prioritization
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What is meant by 'high throughput' as a criterion for prioritized submissions?
CLARIFIED ANSWER: High throughput means tests that can address large volumes, crucial for broad population screening. The FDA prioritizes such large-capacity tests over low-throughput ones.
VERBATIM QUESTION: What is meant by 'high throughput' as a criterion for prioritized submissions?
VERBATIM ANSWER: Yes with the central lab test we are also asking for, you know, it be a high throughput test. So a low-throughput test isn't really going to advance our capability as a country to address the huge numbers of tests that are needed for asymptomatically screening our population. And we're really driving development priorities towards those extremely high throughput tests. And those are the ones that we're prioritizing so simply a new submission, you know, adding asymptomatic screening that doesn't also meet our access.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: high throughput, submission prioritization, population testing
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Are low-throughput tests being deprioritized for EUA submissions due to pandemic priorities?
CLARIFIED ANSWER: The FDA is prioritizing high-throughput tests for EUA submissions to address the need for large-scale asymptomatic screening. Low-throughput tests are not being prioritized currently and will likely not be prioritized in the future.
VERBATIM QUESTION: Are low-throughput tests being deprioritized for EUA submissions due to pandemic priorities?
VERBATIM ANSWER: Yes with the central lab test we are also asking for, you know, it be a high throughput test. So a low-throughput test isn't really going to advance our capability as a country to address the huge numbers of tests that are needed for asymptomatically screening our population. And we're really driving development priorities towards those extremely high throughput tests. And those are the ones that we're prioritizing so simply a new submission, you know, adding asymptomatic screening that doesn't also meet our access. Our access is point-of-care in-home. But if it's a central - if it's moderate to high complexity test and it doesn't have - and it doesn't meet the throughput template it's not going to be prioritized right now and it probably won't be going forward.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission priorities, low-throughput tests, pandemic diagnostic strategies
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Does the FDA have a specific throughput template that developers need to adhere to for prioritization?
CLARIFIED ANSWER: The FDA requires developers to use a high-throughput template to align with current priorities. Low-throughput tests or moderate to high complexity tests not meeting the throughput requirements will not be prioritized.
VERBATIM QUESTION: Does the FDA have a specific throughput template that developers need to adhere to for prioritization?
VERBATIM ANSWER: Yes with the central lab test we are also asking for, you know, it be a high throughput test. So a low-throughput test isn't really going to advance our capability as a country to address the huge numbers of tests that are needed for asymptomatically screening our population. And we're really driving development priorities towards those extremely high throughput tests. And those are the ones that we're prioritizing so simply a new submission, you know, adding asymptomatic screening that doesn't also meet our access. Our access is point-of-care in-home. But if it's a central - if it's moderate to high complexity test and it doesn't have - and it doesn't meet the throughput template it's not going to be prioritized right now and it probably won't be going forward.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA test prioritization, throughput templates, asymptomatic screening
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: What is the FDA's definition of 'access' in terms of point-of-care and in-home testing?
CLARIFIED ANSWER: The FDA defines 'access' as point-of-care and in-home testing.
VERBATIM QUESTION: What is the FDA's definition of 'access' in terms of point-of-care and in-home testing?
VERBATIM ANSWER: Our access is point-of-care in-home. But if it's a central - if it's moderate to high complexity test and it doesn't have - and it doesn't meet the throughput template it's not going to be prioritized right now and it probably won't be going forward.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: definition of 'access', point-of-care testing, in-home testing
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: Will tests that are moderate to high complexity but do not meet high-throughput requirements be deprioritized indefinitely?
CLARIFIED ANSWER: Tests that are moderate to high complexity but do not meet the high-throughput requirements are not being prioritized currently and likely won't be in the future. However, developers can use the regular authorization pathway which remains open.
VERBATIM QUESTION: Will tests that are moderate to high complexity but do not meet high-throughput requirements be deprioritized indefinitely?
VERBATIM ANSWER: Yes with the central lab test we are also asking for, you know, it be a high throughput test. So a low-throughput test isn't really going to advance our capability as a country to address the huge numbers of tests that are needed for asymptomatically screening our population. And we're really driving development priorities towards those extremely high throughput tests. And those are the ones that we're prioritizing so simply a new submission, you know, adding asymptomatic screening that doesn't also meet our access. Our access is point-of-care in-home. But if it's a central - if it's moderate to high complexity test and it doesn't have - and it doesn't meet the throughput template it's not going to be prioritized right now and it probably won't be going forward. The regular full authorization pathway it is open to test developers who don't meet our pandemic priorities, you know, which are probably going to be, you know, pretty similar going forward. And so that pathway is open to them. We are accepting MDUFA applications as I said at the beginning of the call and we're not putting them on hold. They may take a little bit longer than we'd like and the same thing goes for pre-submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Prioritization of tests, High-throughput requirements, Authorization pathways
REVIEW FLAG: False

QA Block 10-8
CLARIFIED QUESTION: Is the full authorization pathway still available for tests that do not align with the current pandemic priorities?
CLARIFIED ANSWER: The full authorization pathway is available for tests that do not meet current pandemic priorities. FDA is accepting MDUFA applications and pre-submissions, though they may experience some delays.
VERBATIM QUESTION: Is the full authorization pathway still available for tests that do not align with the current pandemic priorities?
VERBATIM ANSWER: The regular full authorization pathway it is open to test developers who don't meet our pandemic priorities, you know, which are probably going to be, you know, pretty similar going forward. And so that pathway is open to them. We are accepting MDUFA applications as I said at the beginning of the call and we're not putting them on hold. They may take a little bit longer than we'd like and the same thing goes for pre-submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Full authorization pathway, Pandemic priorities, MDUFA applications
REVIEW FLAG: False

QA Block 10-9
CLARIFIED QUESTION: How long are MDUFA applications currently taking to review?
CLARIFIED ANSWER: FDA is accepting MDUFA applications and pre-submissions without putting them on hold, but reviews may take longer than desired.
VERBATIM QUESTION: How long are MDUFA applications currently taking to review?
VERBATIM ANSWER: We are accepting MDUFA applications as I said at the beginning of the call and we're not putting them on hold. They may take a little bit longer than we'd like and the same thing goes for pre-submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: MDUFA application review times, FDA submission process
REVIEW FLAG: False

QA Block 10-10
CLARIFIED QUESTION: Are pre-submissions being delayed compared to other application types?
CLARIFIED ANSWER: FDA is accepting pre-submissions and MDUFA applications, but they may take longer than expected.
VERBATIM QUESTION: Are pre-submissions being delayed compared to other application types?
VERBATIM ANSWER: We are accepting MDUFA applications as I said at the beginning of the call and we're not putting them on hold. They may take a little bit longer than we'd like and the same thing goes for pre-submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-submission processing, MDUFA applications, Submission delays
REVIEW FLAG: False


#### 11. FDA vs. CMS Roles in Test Categorization

QA Block 11-1
CLARIFIED QUESTION: Is the less than 1% variant mutation not being detected by the Quidel Sofia 2 instrument the reason Medicare is declining payment or re-categorizing it as moderately complex or high complexity?
CLARIFIED ANSWER: The issue involves a misunderstanding, and Medicare has not re-categorized the Quidel Sofia 2. It is authorized under the EUA for point-of-care use in CLIA-waived settings. The FDA recommends reaching out to CMS for clarification on payment matters.
VERBATIM QUESTION: Is the less than 1% variant mutation not being detected by the Quidel Sofia 2 instrument the reason Medicare is declining payment or re-categorizing it as moderately complex or high complexity?
VERBATIM ANSWER: Yes. This has come up - I'm not going to be able to give you full information because it really is out of CMS and so we'll recommend that you reach out to CMS. If you email the CLIA program they'll be able to address your question. There is what I understand from talking to our CMS colleagues is that there's a misunderstanding and there's not - they're - they haven't re-categorized anything. The Quidel Sofia is authorized under their EUA for point of care which is CLIA certificate of waiver setting. And if your reach out to CMS they'll be able to clarify the payment side of things for you.
SPEAKER QUESTION: Maria Ramos
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Quidel Sofia 2 instrument, Medicare payment issues, CLIA/EUA categorization
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: What role does the FDA play versus CLIA in re-categorizing testing devices?
CLARIFIED ANSWER: The FDA is responsible for determining test settings and categorizing them under CLIA, except during emergencies where formal categorization isn't done but parallel authorizations might be issued. CLIA/CMS handle lab certifications and payment decisions, including coding issues.
VERBATIM QUESTION: What role does the FDA play versus CLIA in re-categorizing testing devices?
VERBATIM ANSWER: So again they have not re-categorized. Their - what they point out is specific to payment and is a coding issue. The FDA is responsible for, you know, outside of an emergency, we do a CLIA categorization. Under the EUA we don't do a formal categorization but we authorize for specific settings which is sort of parallel to that CLIA categorization that we would do on a full marketing submission. But their - that does fall under FDA, the determining what settings a test can be used in under that authorization. The CLIA and CMS side is, you know, authorized on the CLIA side authorizing or certifying the labs for a specific level of testing and on the reimbursement and payment side of things determining what gets paid for. And I think that this really is a misunderstanding based on possibly the way that they worded their document, I'm not sure, and they'll be able to resolve that.
SPEAKER QUESTION: Maria Ramos
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA and CLIA roles, Test categorization, Regulatory processes
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: What are the differences between FDA's test settings categorization under EUA versus a full marketing authorization?
CLARIFIED ANSWER: Under EUA, FDA authorizes tests for specific settings, which is parallel to CLIA categorization under full marketing authorization. For non-EUA tests, FDA categorizes them as high, moderate, or waived complexity, while CLIA certifies labs and CMS determines payment.
VERBATIM QUESTION: What are the differences between FDA's test settings categorization under EUA versus a full marketing authorization?
VERBATIM ANSWER: Under the EUA we don't do a formal categorization but we authorize for specific settings which is sort of parallel to that CLIA categorization that we would do on a full marketing submission. But their - that does fall under FDA, the determining what settings a test can be used in under that authorization. The CLIA and CMS side is, you know, authorized on the CLIA side authorizing or certifying the labs for a specific level of testing and on the reimbursement and payment side of things determining what gets paid for. And I think that this really is a misunderstanding based on possibly the way that they worded their document, I'm not sure, and they'll be able to resolve that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA test settings, EUA versus full marketing, CLIA categorization
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: What steps should developers take if encountering reimbursement issues with CMS regarding tests authorized for point-of-care use?
CLARIFIED ANSWER: Developers should contact the specific test developer for assistance with reimbursement issues, as they may be able to help.
VERBATIM QUESTION: What steps should developers take if encountering reimbursement issues with CMS regarding tests authorized for point-of-care use?
VERBATIM ANSWER: And if you haven't already, you know, it's good to chat with the specific developer of a test that you're having any sort of reimbursement issues with as they potentially can help as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reimbursement issues, CMS, point-of-care testing
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: What does it mean for a test to be 'deemed waived' under an EUA?
CLARIFIED ANSWER: Under EUA, the FDA does not perform formal CLIA categorizations but designates tests for appropriate use settings, calling this process 'deeming' a test waived. Full categorization happens during final authorization.
VERBATIM QUESTION: What does it mean for a test to be 'deemed waived' under an EUA?
VERBATIM ANSWER: And just for clarity under law, under federal law it's our office that is the office that under normal circumstances categorizes tests as high, moderate or waived. Under EUA, we are not making formal categorizations, but it is still falls to our office to do this. And so we're calling it deeming a test for categorization. This most - mostly applies to those tests that we're deeming as waived and we're not currently till those tests come for full authorization we are not doing a formal categorization. And as Toby mentioned this test was, it sounds like appropriately deemed waived by the FDA, by our office and so this is some sort of paperwork problem and hopefully it quickly resolves.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA test categorization, Deemed waived tests, FDA regulatory process
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: How can developers determine if their test reimbursement issues are related to coding or administrative misunderstandings?
CLARIFIED ANSWER: Developers should contact the specific test developer experiencing reimbursement issues, as they might provide assistance.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: And if you haven't already, you know, it's good to chat with the specific developer of a test that you're having any sort of reimbursement issues with as they potentially can help as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test reimbursement, developer support
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: What role does FDA play in test categorization when CMS changes payment policies or coding?
CLARIFIED ANSWER: The FDA determines test settings under EUA, parallel to CLIA categorization under full marketing. Under law, FDA categorizes tests (high, moderate, or waived). CMS handles lab certification and payment policies. Issues appear to stem from payment coding misunderstandings.
VERBATIM QUESTION: What role does FDA play in test categorization when CMS changes payment policies or coding?
VERBATIM ANSWER: So again they have not re-categorized. Their - what they point out is specific to payment and is a coding issue. The FDA is responsible for, you know, outside of an emergency, we do a CLIA categorization. Under the EUA we don't do a formal categorization but we authorize for specific settings which is sort of parallel to that CLIA categorization that we would do on a full marketing submission. But their - that does fall under FDA, the determining what settings a test can be used in under that authorization. The CLIA and CMS side is, you know, authorized on the CLIA side authorizing or certifying the labs for a specific level of testing and on the reimbursement and payment side of things determining what gets paid for. And I think that this really is a misunderstanding based on possibly the way that they worded their document, I'm not sure, and they'll be able to resolve that.
SPEAKER QUESTION: Maria Ramos
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA role in test categorization, CLIA categorization, CMS payment policies
REVIEW FLAG: False

QA Block 11-10
CLARIFIED QUESTION: How does the communication between FDA and CMS affect diagnostic test developers?
CLARIFIED ANSWER: FDA works with CMS to address communication issues related to diagnostic tests. For specific inquiries such as coding and payment, developers are encouraged to contact CMS directly since any misunderstandings likely stem from their documentation or coding guidelines.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Yes. This has come up - I'm not going to be able to give you full information because it really is out of CMS and so we'll recommend that you reach out to CMS. If you email the CLIA program they'll be able to address your question. There is what I understand from talking to our CMS colleagues is that there's a misunderstanding and there's not - they're - they haven't re-categorized anything. The Quidel Sofia is authorized under their EUA for point of care which is CLIA certificate of waiver setting. And if your reach out to CMS they'll be able to clarify the payment side of things for you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA-CMS communication, Diagnostic test categorization, Reimbursement concerns
REVIEW FLAG: False


#### 12. Defining Point-of-Care Settings for Clinical Research Sites

QA Block 12-1
CLARIFIED QUESTION: Do clinical research organization sites qualify as a point of care setting?
CLARIFIED ANSWER: It depends. FDA generally sees typical busy primary care clinics as point-of-care settings. Other settings may qualify but need to be discussed with FDA through a pre-EUA submission.
VERBATIM QUESTION: Do clinical research organization sites qualify as a point of care setting?
VERBATIM ANSWER: I think so. I mean it depends. We're really looking in the point-of-care studies the typical setting is a typical busy, you know, primary care sort of facility. And we're looking for the ability of folks and, you know, healthcare workers who are not trained in laboratory and in the midst of their busy daily schedules to be able to use the test and get accurate results because in the real world that's what's happening. And if you've ever been to a busy point of care clinic these folks, they're juggling a lot of balls. And want to make sure that the device is robust enough, the instructions are robust enough that they still get accurate results. So that is the ideal. If you're contemplating settings other than what I just described I would recommend submitting a pre-EUA and describing it and getting and having a discussion with our staff on whether that's appropriate or not. We don't want you to go ahead and do a study and then it be lacking in some ways.
SPEAKER QUESTION: Lisa Homertz
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point of care settings, clinical research organizations, FDA pre-EUA process
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: What are the requirements or expectations for a setting to qualify as a point-of-care location?
CLARIFIED ANSWER: The FDA looks for point-of-care settings to resemble busy primary care facilities where healthcare workers, often not laboratory-trained, can still accurately use tests despite their demanding schedules. If other settings are considered, FDA advises submitting a pre-EUA for discussion.
VERBATIM QUESTION: What are the requirements or expectations for a setting to qualify as a point-of-care location?
VERBATIM ANSWER: We're really looking in the point-of-care studies the typical setting is a typical busy, you know, primary care sort of facility. And we're looking for the ability of folks and, you know, healthcare workers who are not trained in laboratory and in the midst of their busy daily schedules to be able to use the test and get accurate results because in the real world that's what's happening. And if you've ever been to a busy point of care clinic these folks, they're juggling a lot of balls. And want to make sure that the device is robust enough, the instructions are robust enough that they still get accurate results. So that is the ideal. If you're contemplating settings other than what I just described I would recommend submitting a pre-EUA and describing it and getting and having a discussion with our staff on whether that's appropriate or not. We don't want you to go ahead and do a study and then it be lacking in some ways.
SPEAKER QUESTION: Lisa Homertz
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care definitions, FDA requirements, pre-EUA process
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: What factors does the FDA consider when determining if a facility other than a primary care clinic can be used in point-of-care studies?
CLARIFIED ANSWER: For point-of-care studies, the FDA primarily considers whether the setting resembles a busy primary care facility where non-laboratory-trained healthcare workers use the test accurately amidst their normal duties. If an alternate setting is proposed, the FDA recommends submitting a pre-EUA to assess its appropriateness.
VERBATIM QUESTION: What factors does the FDA consider when determining if a facility other than a primary care clinic can be used in point-of-care studies?
VERBATIM ANSWER: I think so. I mean it depends. We're really looking in the point-of-care studies the typical setting is a typical busy, you know, primary care sort of facility. And we're looking for the ability of folks and, you know, healthcare workers who are not trained in laboratory and in the midst of their busy daily schedules to be able to use the test and get accurate results because in the real world that's what's happening. And if you've ever been to a busy point of care clinic these folks, they're juggling a lot of balls. And want to make sure that the device is robust enough, the instructions are robust enough that they still get accurate results. So that is the ideal. If you're contemplating settings other than what I just described I would recommend submitting a pre-EUA and describing it and getting and having a discussion with our staff on whether that's appropriate or not. We don't want you to go ahead and do a study and then it be lacking in some ways.
SPEAKER QUESTION: Lisa Homertz
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care studies, Facility requirements, Pre-EUA process
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: Is there a process to pre-determine the appropriateness of a facility for point-of-care studies before conducting a study?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA and discussing with FDA staff to determine if a facility is appropriate for point-of-care studies before conducting the study.
VERBATIM QUESTION: Is there a process to pre-determine the appropriateness of a facility for point-of-care studies before conducting a study?
VERBATIM ANSWER: If you're contemplating settings other than what I just described I would recommend submitting a pre-EUA and describing it and getting and having a discussion with our staff on whether that's appropriate or not. We don't want you to go ahead and do a study and then it be lacking in some ways.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA process, point-of-care study requirements
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: How can developers ensure that instructions for use and device robustness meet FDA requirements for point-of-care settings?
CLARIFIED ANSWER: The FDA requires point-of-care device instructions and robustness to support use in busy primary care settings by untrained healthcare workers to ensure accurate results. Developers should test under realistic conditions.
VERBATIM QUESTION: How can developers ensure that instructions for use and device robustness meet FDA requirements for point-of-care settings?
VERBATIM ANSWER: We're really looking in the point-of-care studies the typical setting is a typical busy, you know, primary care sort of facility. And we're looking for the ability of folks and, you know, healthcare workers who are not trained in laboratory and in the midst of their busy daily schedules to be able to use the test and get accurate results because in the real world that's what's happening. And if you've ever been to a busy point of care clinic these folks, they're juggling a lot of balls. And want to make sure that the device is robust enough, the instructions are robust enough that they still get accurate results. So that is the ideal.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care settings, device robustness, FDA requirements
REVIEW FLAG: False


#### 13. Defining High Throughput and Testing Prioritization Criteria

QA Block 13-1
CLARIFIED QUESTION: If a test is not on a high-throughput platform and cannot test at least 150 samples at once but can still test multiple samples, is it considered a lower priority than other point-of-care tests or high-throughput platform tests?
CLARIFIED ANSWER: FDA prioritizes tests that meet thresholds for point-of-care, high-throughput, or significant home testing access. Tests not meeting these bars, such as neutralizing antibody assays with limited utility, are deemed lower priority during the pandemic.
VERBATIM QUESTION: If a test is not on a high-throughput platform and cannot test at least 150 samples at once but can still test multiple samples, is it considered a lower priority than other point-of-care tests or high-throughput platform tests?
VERBATIM ANSWER: Yes so again we're looking at access. And so it does - it's home, it's point- of-care or it's high throughput. It really needs to pass those bars right now first, those thresholds. Having a great neutralizing antibody assay that can't really help that many people is not going to address the country's needs right now. So we are, you know, this is - you know, these priorities are out there for clear reasons. One is to inform developers of what we're not prioritizing. And it also is to hopefully stimulate developers to develop the tests that are really needed at this stage of the pandemic. Okay?
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test prioritization, high-throughput vs point-of-care, pandemic testing needs
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: Can you define high throughput in the context of diagnostic testing?
CLARIFIED ANSWER: The FDA is not currently publishing a fixed definition of high throughput, as it may evolve during the pandemic. Developers should consult the FDA via the pre-EUA process to determine if their test meets current priorities.
VERBATIM QUESTION: Can you define high throughput in the context of diagnostic testing?
VERBATIM ANSWER: So, yes as we said before if you want to check and see if your test will meet current priorities, you know, do send in a pre-EUA with relevant information for us to assess that. You don't have to fill out a full pre-EUA if you're going to use the templates as in the template recommendations as intended. You can simply say our one question is do we need the high throughput at all? That is something that we're not publishing right now because as we go through the pandemic that may - they may elevate and if the needs change. So it's best just to check with our staff through the pre-EUA process to see if your test would currently match our priorities.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: High throughput, Diagnostic test priorities, Pre-EUA process
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: Do developers need to check if their test meets high-throughput requirements through the pre-EUA process?
CLARIFIED ANSWER: Yes, developers should check through the pre-EUA process to see if their test meets high-throughput or other current priorities. A full pre-EUA is not necessary if using the recommended templates.
VERBATIM QUESTION: Do developers need to check if their test meets high-throughput requirements through the pre-EUA process?
VERBATIM ANSWER: So, yes as we said before if you want to check and see if your test will meet current priorities, you know, do send in a pre-EUA with relevant information for us to assess that. You don't have to fill out a full pre-EUA if you're going to use the templates as in the template recommendations as intended. You can simply say our one question is do we need the high throughput at all? That is something that we're not publishing right now because as we go through the pandemic that may - they may elevate and if the needs change. So it's best just to check with our staff through the pre-EUA process to see if your test would currently match our priorities.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: high-throughput requirements, pre-EUA process, test prioritization
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: What constitutes a test being categorized as "addressing unmet needs" from the FDA's perspective?
CLARIFIED ANSWER: Tests that address unmet needs must meet specific priorities such as accessibility (home, point-of-care, or high throughput), and they should address the country's current needs effectively. The FDA sets these priorities to guide developers and encourage tests that are essential for the pandemic stage.
VERBATIM QUESTION: What constitutes a test being categorized as "addressing unmet needs" from the FDA's perspective?
VERBATIM ANSWER: Yes so again we're looking at access. And so it does - it's home, it's point- of-care or it's high throughput. It really needs to pass those bars right now first, those thresholds. Having a great neutralizing antibody assay that can't really help that many people is not going to address the country's needs right now. So we are, you know, this is - you know, these priorities are out there for clear reasons. One is to inform developers of what we're not prioritizing. And it also is to hopefully stimulate developers to develop the tests that are really needed at this stage of the pandemic. Okay?
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: unmet needs criteria, test prioritization, FDA guidance
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: Are neutralizing antibody tests currently considered a priority by the FDA?
CLARIFIED ANSWER: Neutralizing antibody tests are not currently prioritized by the FDA unless they meet specific criteria such as high throughput, home, or point-of-care accessibility.
VERBATIM QUESTION: Are neutralizing antibody tests currently considered a priority by the FDA?
VERBATIM ANSWER: Yes so again we're looking at access. And so it does - it's home, it's point- of-care or it's high throughput. It really needs to pass those bars right now first, those thresholds. Having a great neutralizing antibody assay that can't really help that many people is not going to address the country's needs right now. So we are, you know, this is - you know, these priorities are out there for clear reasons. One is to inform developers of what we're not prioritizing. And it also is to hopefully stimulate developers to develop the tests that are really needed at this stage of the pandemic.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: neutralizing antibody tests, FDA priorities, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: What are the thresholds for tests to be classified as point-of-care, home, or high-throughput under current FDA guidelines?
CLARIFIED ANSWER: FDA prioritizes tests that meet thresholds for home, point-of-care, or high-throughput use to address pandemic needs. Tests that do not align with these priorities, like those less widely applicable, are not emphasized.
VERBATIM QUESTION: What are the thresholds for tests to be classified as point-of-care, home, or high-throughput under current FDA guidelines?
VERBATIM ANSWER: Yes so again we're looking at access. And so it does - it's home, it's point- of-care or it's high throughput. It really needs to pass those bars right now first, those thresholds. Having a great neutralizing antibody assay that can't really help that many people is not going to address the country's needs right now. So we are, you know, this is - you know, these priorities are out there for clear reasons. One is to inform developers of what we're not prioritizing. And it also is to hopefully stimulate developers to develop the tests that are really needed at this stage of the pandemic.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA test classification, Thresholds for test prioritization
REVIEW FLAG: False

QA Block 13-7
CLARIFIED QUESTION: Is the FDA prioritizing tests beyond the stated categories (home, point-of-care, high-throughput) depending on pandemic stages?
CLARIFIED ANSWER: The FDA prioritizes home, point-of-care, and high-throughput tests as they address the country's needs. Priorities are set to guide developers and stimulate the creation of needed tests during the pandemic.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Yes so again we're looking at access. And so it does - it's home, it's point- of-care or it's high throughput. It really needs to pass those bars right now first, those thresholds. Having a great neutralizing antibody assay that can't really help that many people is not going to address the country's needs right now. So we are, you know, this is - you know, these priorities are out there for clear reasons. One is to inform developers of what we're not prioritizing. And it also is to hopefully stimulate developers to develop the tests that are really needed at this stage of the pandemic. Okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA test prioritization, COVID-19 diagnostics prioritization
REVIEW FLAG: False

QA Block 13-8
CLARIFIED QUESTION: Can developers provide a partial pre-EUA submission if they follow template recommendations?
CLARIFIED ANSWER: Developers can submit a partial pre-EUA if they follow the FDA's template recommendations properly.
VERBATIM QUESTION: Can developers provide a partial pre-EUA submission if they follow template recommendations?
VERBATIM ANSWER: You don't have to fill out a full pre-EUA if you're going to use the templates as in the template recommendations as intended.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA submission, template recommendations, FDA process
REVIEW FLAG: False

QA Block 13-9
CLARIFIED QUESTION: Will high-throughput test requirements change depending on future pandemic needs?
CLARIFIED ANSWER: The FDA is not publishing clear requirements for high-throughput tests at this time, as these requirements may change depending on future pandemic needs. Developers should consult through the pre-EUA process to confirm alignment with current FDA priorities.
VERBATIM QUESTION: Will high-throughput test requirements change depending on future pandemic needs?
VERBATIM ANSWER: That is something that we're not publishing right now because as we go through the pandemic that may - they may elevate and if the needs change. So it's best just to check with our staff through the pre-EUA process to see if your test would currently match our priorities.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: high-throughput test requirements, pandemic needs, pre-EUA process
REVIEW FLAG: False


#### 14. FDA Guidance on Home Antigen Test Usability Studies

QA Block 14-1
CLARIFIED QUESTION: For an antigen rapid test for home use, if an adult collects a sample from another person such as a child, can that same adult then run the test on themselves and be counted in the self-test group, or do we need 100 unique patients?
CLARIFIED ANSWER: The FDA believes it is acceptable for the same adult to self-collect and collect a sample from a child, allowing a more efficient study, as long as usability and safety are demonstrated.
VERBATIM QUESTION: For an antigen rapid test for home use, if an adult collects a sample from another person such as a child, can that same adult then run the test on themselves and be counted in the self-test group, or do we need 100 unique patients?
VERBATIM ANSWER: I believe you can use that same adult to self-collect and to collect the child. And yes, so I think that's acceptable to make that a more efficient study. We'relooking at usability of self-collection as well as usability of an adult in a home situation collecting a child and making sure that the adults can, you know, adults can do both things well and safely.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability study, self-testing vs child testing, efficiency
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: Should the comparator for an anterior nasal swab antigen test for home use be only an anterior nasal swab PCR test, or could it also be a nasopharyngeal swab PCR test?
CLARIFIED ANSWER: The comparator can be a nasopharyngeal, mid-turbinate, or anterior nasal swab, as long as it is a high-sensitivity molecular test with an extraction step. The FDA advises checking with them to confirm the comparator is acceptable.
VERBATIM QUESTION: Should the comparator for an anterior nasal swab antigen test for home use be only an anterior nasal swab PCR test, or could it also be a nasopharyngeal swab PCR test?
VERBATIM ANSWER: It can be a nasopharyngeal swab. It can be a mid-turbinate swab. It can be an anterior nasal swab. We recommend both nares on the anterior nasal swabs. What's most important is that it's a high-sensitivity molecular test that has the - an extraction step. And we do recommend that developers check in with the FDA to make sure that the comparator is going to be an acceptable comparatorahead of time so that there's just no having to redo anything, okay?
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: comparator types, nasal swab diagnostics, test validation
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: Even if a saliva test is a high-sensitivity PCR test, is it not acceptable as a comparator because it is not the same sample type?
CLARIFIED ANSWER: The FDA does not recommend saliva as a sample type for comparator tests due to ongoing issues with it.
VERBATIM QUESTION: Even if a saliva test is a high-sensitivity PCR test, is it not acceptable as a comparator because it is not the same sample type?
VERBATIM ANSWER: Saliva continues to be a problematic sample. And we're seeing issues with it is a sample type. And so we're not recommending it is a sample type for a comparator test.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva as sample type, comparator testing, diagnostic test recommendations
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: How should test developers contact the FDA to verify if a comparator test is acceptable?
CLARIFIED ANSWER: Test developers should contact the FDA in advance to verify if the comparator is acceptable to ensure no rework is required and the test can be properly assessed.
VERBATIM QUESTION: How should test developers contact the FDA to verify if a comparator test is acceptable?
VERBATIM ANSWER: And we do recommend that developers check in with the FDA to make sure that the comparator is going to be an acceptable comparator ahead of time so that there's just no having to redo anything, okay? Just check with us. We want to make sure that you're using an appropriate test that will allow us to make an assessment on whether the test can be authorized or not.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: comparator test verification, FDA consultation
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: What are the recommended sample collection methods for anterior nasal swabs during usability studies?
CLARIFIED ANSWER: The FDA recommends anterior nasal swabs with both nares sampled, but nasopharyngeal or mid-turbinate swabs are also acceptable. The comparator must be a high-sensitivity molecular test with an extraction step. Developers should confirm acceptability with the FDA.
VERBATIM QUESTION: What are the recommended sample collection methods for anterior nasal swabs during usability studies?
VERBATIM ANSWER: It can be a nasopharyngeal swab. It can be a mid-turbinate swab. It can be an anterior nasal swab. We recommend both nares on the anterior nasal swabs. What's most important is that it's a high-sensitivity molecular test that has the - an extraction step. And we do recommend that developers check in with the FDA to make sure that the comparator is going to be an acceptable comparator.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample collection methods, anterior nasal swabs, usability studies
REVIEW FLAG: False

QA Block 14-7
CLARIFIED QUESTION: For usability studies, how might having the same individual perform two roles (self-test and testing another person) impact the broader analysis of instructional usability?
CLARIFIED ANSWER: Having the same individual perform self-testing and testing another person can reduce the overall size and diversity of the usability study, potentially impacting the evaluation of instructions. Developers are advised to assess this and consult with the FDA for further discussion.
VERBATIM QUESTION: For usability studies, how might having the same individual perform two roles (self-test and testing another person) impact the broader analysis of instructional usability?
VERBATIM ANSWER: And just to add a little bit more on your question about the usability study since the intent of the usability study is to assess how well the user can follow the instructions while the, you know, having the same person perform both on themselves and on another individual would be assessing different aspects of those instructions, it would, you know, potentially impact the ability to evaluate, you know, how well a larger group can use the instructions. So, you know, you're sort of reducing the size of your usability study effectively. So you may want to take that into consideration in case that may impact your analysis for the results and you may want to send a note to the inbox to discuss some of the further nuances there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: usability study design, impact on analysis
REVIEW FLAG: False

QA Block 14-8
CLARIFIED QUESTION: What are the potential issues associated with using saliva as a sample type for comparator tests?
CLARIFIED ANSWER: The FDA does not recommend using saliva as a sample type for comparator tests due to ongoing issues with its reliability as a sample type.
VERBATIM QUESTION: What are the potential issues associated with using saliva as a sample type for comparator tests?
VERBATIM ANSWER: Saliva continues to be a problematic sample. And we're seeing issues with it is a sample type. And so we're not recommending it is a sample type for a comparator test.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva sample issues, Comparator test recommendations
REVIEW FLAG: False

QA Block 14-9
CLARIFIED QUESTION: Why is it recommended to verify comparator test appropriateness with the FDA in advance?
CLARIFIED ANSWER: The FDA recommends verifying comparator test appropriateness in advance to avoid potential rework and ensure the test used is suitable for authorization assessment.
VERBATIM QUESTION: Why is it recommended to verify comparator test appropriateness with the FDA in advance?
VERBATIM ANSWER: We do recommend that developers check in with the FDA to make sure that the comparator is going to be an acceptable comparatorahead of time so that there's just no having to redo anything, okay? Just check with us. We want to make sure that you're using an appropriate test that will allow us to make an assessment on whether the test can be authorized or not.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator test verification, FDA guidance
REVIEW FLAG: False


#### 15. FDA Policy on EUA Submissions for Antibody Tests

QA Block 15-2
CLARIFIED QUESTION: Are there plans to phase out EUA submissions for certain types of tests in the near future?
CLARIFIED ANSWER: The FDA does not plan to phase out EUA submissions for serology tests, but it is prioritizing high-throughput and certain other types of tests while declining to review others like lateral flow assays for high-complexity labs.
VERBATIM QUESTION: Are there plans to phase out EUA submissions for certain types of tests in the near future?
VERBATIM ANSWER: That's incorrect on serology tests but we are on - if a test is not high throughput we are declining to review as part of a prioritization process. So if someone say has a lateral flow assay and they're only validating it for a high complexity lab that's not currently meeting our priority. Serology tests that are point of care home collection we're still reviewing if they are complete applications. And if they are high throughput tests, central lab tests as we've authorized a number of them, we are continuing to review those. So I'm not sure where you get your information but it's not correct.
SPEAKER QUESTION: Michael Zhang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission policies, Test prioritization, Serology tests
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: What is the FDA's prioritization process for reviewing EUA submissions for COVID-19 tests?
CLARIFIED ANSWER: The FDA prioritizes reviewing EUA submissions based on test type and application. High throughput tests and complete applications for point-of-care and home collection serology tests are being reviewed. Tests not fitting these criteria, such as lateral flow assays for high complexity labs, are not prioritized.
VERBATIM QUESTION: What is the FDA's prioritization process for reviewing EUA submissions for COVID-19 tests?
VERBATIM ANSWER: That's incorrect on serology tests but we are on - if a test is not high throughput we are declining to review as part of a prioritization process. So if someone say has a lateral flow assay and they're only validating it for a high complexity lab that's not currently meeting our priority. Serology tests that are point of care home collection we're still reviewing if they are complete applications. And if they are high throughput tests, central lab tests as we've authorized a number of them, we are continuing to review those.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA review process, COVID-19 diagnostics, FDA priorities
REVIEW FLAG: False

QA Block 15-5
CLARIFIED QUESTION: Under what conditions will the FDA continue reviewing EUA submissions for serology tests?
CLARIFIED ANSWER: The FDA continues to review EUA submissions for serology tests if the submissions are complete and either for point-of-care home collection or high-throughput, central lab formats.
VERBATIM QUESTION: Under what conditions will the FDA continue reviewing EUA submissions for serology tests?
VERBATIM ANSWER: That's incorrect on serology tests but we are on - if a test is not high throughput we are declining to review as part of a prioritization process. So if someone say has a lateral flow assay and they're only validating it for a high complexity lab that's not currently meeting our priority. Serology tests that are point of care home collection we're still reviewing if they are complete applications. And if they are high throughput tests, central lab tests as we've authorized a number of them, we are continuing to review those.
SPEAKER QUESTION: Michael Zhang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submissions, serology tests, FDA diagnostic priorities
REVIEW FLAG: False

QA Block 15-6
CLARIFIED QUESTION: Is the availability of home collection or point-of-care features a factor in EUA review prioritization for serology tests?
CLARIFIED ANSWER: The FDA continues to review EUA submissions for serology tests with home collection or point-of-care features if they are complete applications.
VERBATIM QUESTION: Is the availability of home collection or point-of-care features a factor in EUA review prioritization for serology tests?
VERBATIM ANSWER: Serology tests that are point of care home collection we're still reviewing if they are complete applications.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA prioritization, Serology tests, Home collection/point-of-care features
REVIEW FLAG: False

QA Block 15-7
CLARIFIED QUESTION: Where can the presentation materials and transcript from today's town hall be accessed?
CLARIFIED ANSWER: The presentation materials and transcript from today's town hall will be available on the CDRH Learn webpage (www.fda.gov/training/cdrhlearn) by Friday, May 21.
VERBATIM QUESTION: Where can the presentation materials and transcript from today's town hall be accessed?
VERBATIM ANSWER: Today's presentation and transcript will be made available on the CDRH Learn Web page at www.fda.gov/training/cdrhlearn by Friday, May 21. If you have additional questions about today's presentation please email cdrh-eua- templates@fda.hhs.gov.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Irene Aihie (FDA Moderator)
TOPICS: Access to town hall materials, FDA resources
REVIEW FLAG: False

QA Block 15-8
CLARIFIED QUESTION: How can participants provide feedback after the conclusion of the virtual town hall?
CLARIFIED ANSWER: Participants can provide feedback on the virtual town hall by completing a short 13-question survey available at www.fda.gov/cdrhwebinar.
VERBATIM QUESTION: How can participants provide feedback after the conclusion of the virtual town hall?
VERBATIM ANSWER: Following the conclusion of today's virtual town hall please complete a short 13 question survey about your FDA CDRH virtual town hall experience. The survey can be found now on www.fda.gov/cdrhwebinar.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Irene Aihie (FDA Moderator)
TOPICS: Feedback process, Virtual town hall, Survey information
REVIEW FLAG: False

### removed qa blocks
QA Block 2-3
CLARIFIED QUESTION: What type of comparator does the FDA recommend for a lateral flow rapid antigen test clinical study with nasal samples?
CLARIFIED ANSWER: FDA recommends using a high-sensitivity PCR test with a nasal specimen as the comparator for clinical studies of lateral flow rapid antigen tests. Saliva specimens and antigen tests are not acceptable as comparators.
VERBATIM QUESTION: What type of comparator does the FDA recommend for a lateral flow rapid antigen test clinical study with nasal samples?
VERBATIM ANSWER: We do recommend a high-sensitivity PCR using a nasal specimen as a comparator. Neither saliva specimens nor antigen tests are acceptable comparators. You should select a high-sensitivity PCR that is authorized for home collection and use the home collection kit with which that selected comparator test is authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Comparator for lateral flow test, Clinical study recommendations
REVIEW FLAG: False

QA Block 7-1
CLARIFIED QUESTION: What would be acceptable to use as the clinical matrix for a saliva antigen test?
CLARIFIED ANSWER: FDA suggests submitting a pre-EUA for saliva antigen tests. Artificial samples are not allowed, but banked or contrived samples (e.g., pooled saliva spiked with inactivated virus) can be used for analytical studies. Saliva is considered a challenging sample type for antigen tests.
VERBATIM QUESTION: What would be acceptable to use as the clinical matrix for a saliva antigen test?
VERBATIM ANSWER: You know, I recommend submitting a pre-EUA for your saliva antigen test and your plans. Typically we won't allow, you know, completely artificial samples for anything right now including saliva. And the use of banked samples especially for analytical study is fine. The use of contrived samples is generally okay for analytical studies meaning you take a negative patient saliva or pooled saliva and you spike in virus, whole virus inactivated will work. Or you can dilute a positive patient saliva sample into a negative pool in order to get the dilutions that you, you know, would want for your analytical studies. But again we don't have recommendations out there on validation of saliva antigen tests. We do think that's a particularly challenging sample type for antigen tests.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: clinical matrix for saliva tests, use of artificial or banked samples, antigen test validation
REVIEW FLAG: False

QA Block 7-10
CLARIFIED QUESTION: Why are freeze-thaw studies required for molecular testing and how do they differ from the requirements for antigen testing?
CLARIFIED ANSWER: Freeze-thaw studies are required for molecular testing to assess any potential impacts, as molecular tests typically include an extraction step. Antigen tests, on the other hand, show a consistent sensitivity increase with the freeze-thaw cycle, which could lead to artificial results and does not reflect real-world performance.
VERBATIM QUESTION: Why are freeze-thaw studies required for molecular testing and how do they differ from the requirements for antigen testing?
VERBATIM ANSWER: Antigen tests are more challenging because we've observed that the freeze-thaw process seems to increase access shall we say to the antigen. And it's an artificial increase in assay sensitivity that is hard to control and understand. And we really want to understand real-world performance. So, you know, anything that doesn't follow sort of, you know, an, you know, our sort of standard recommendations for antigen tests, again I do recommend that you submit a pre-EUA and ask for any, you know, flexibility that you need to develop your test. But molecular is a little bit different because they typically have an extraction step and, you know, for those essays that - although we do examine about whether freeze-thaw does impact molecular as well so we do ask for freestyle studies. But with antigen it's been pretty consistent that the sensitivity increases with the freeze-thaw cycle.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Freeze-thaw studies, Molecular vs antigen testing, Sensitivity and performance
REVIEW FLAG: False

QA Block 8-1
CLARIFIED QUESTION: When will the decision summary for the BioFire de novo assay be made available?
CLARIFIED ANSWER: The FDA cannot predict when the decision summary for the BioFire de novo assay will be available as it must undergo a review process to check for proprietary information. The FDA will post it as soon as possible.
VERBATIM QUESTION: When will the decision summary for the BioFire de novo assay be made available?
VERBATIM ANSWER: It goes through a process of looking for any proprietary information that about the assay that we authorized that shouldn't be disclosed publicly. So it leaves our office and it's go through this process and we're not entirely in control of it and we can't, just like guidance, we can't predict when it's going to come out. However for those developers for molecular serology and antigen tests that want to pursue full authorization, as I said we're accepting Pre-Subs for COVID related applications. And as soon as we can post that that decision, we will.
SPEAKER QUESTION: Don Caffiter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: BioFire assay decision summary, FDA review process, COVID test authorization
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: What are the sensitivity limit requirements for a centralized laboratory test versus a home use or point-of-care test?
CLARIFIED ANSWER: FDA stated that the minimum sensitivity (PPA) for home or point-of-care molecular tests is 80%, with authorization granted for results between 80% and 95% PPA when compared to high-sensitivity centralized molecular tests. Specific thresholds for serology and other applications are provided in templates.
VERBATIM QUESTION: What are the sensitivity limit requirements for a centralized laboratory test versus a home use or point-of-care test?
VERBATIM ANSWER: Yes clinical sensitivity or positive percent agreement to a comparator or to the, you know, the test of record, you know, for molecular and serology they would be different answers for that. I think we have - well I know that the home template for antigen molecular spells this out. And then I think we have a home collection template for serology. So you should be able to get a good idea. Basically for serology testing we're really sort of have set levels of sensitivity or PPA recommendations as well as specificity or MPA. For - and for home - and for point of care molecular it's 80% is the floor that we recommend. We really like to see good concordance to central and molecular tests for all molecular tests whether they be in-home or point-of-care. But we will authorize molecular tests between 80% and 95% PPA compared to a high sensitivity central molecular tests. And the same thing for home molecular tests. And then there are various thresholds for different applications such as if you want OTC and there's different pathways for the OTC. And those are all laid out fairly clearly in our templates so I'm not going to go over those again right now.
SPEAKER QUESTION: Richard Darren
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sensitivity limit requirements, home use vs centralized diagnostics
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: Can CLIA re-categorize testing devices?
CLARIFIED ANSWER: CLIA does not re-categorize testing devices; this responsibility falls under the FDA, which categorizes tests into high, moderate, or waived. Under EUA, tests are deemed for categorization rather than formally categorized. CLIA focuses on lab certifications.
VERBATIM QUESTION: Can CLIA re-categorize testing devices?
VERBATIM ANSWER: So again they have not re-categorized. Their - what they point out is specific to payment and is a coding issue. The FDA is responsible for, you know, outside of an emergency, we do a CLIA categorization. Under the EUA we don't do a formal categorization but we authorize for specific settings which is sort of parallel to that CLIA categorization that we would do on a full marketing submission. But their - that does fall under FDA, the determining what settings a test can be used in under that authorization. The CLIA and CMS side is, you know, authorized on the CLIA side authorizing or certifying the labs for a specific level of testing and on the reimbursement and payment side of things determining what gets paid for. And I think that this really is a misunderstanding based on possibly the way that they worded their document, I'm not sure, and they'll be able to resolve that.
SPEAKER QUESTION: Maria Ramos
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA categorization, EUA process, FDA authority
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: How does the FDA handle test categorization under an EUA compared to non-emergency situations?
CLARIFIED ANSWER: Under an EUA, the FDA does not perform formal categorizations but authorizes tests for specific settings, which is parallel to CLIA categorization in non-emergency situations. Formal categorizations are not performed until full marketing submissions.
VERBATIM QUESTION: How does the FDA handle test categorization under an EUA compared to non-emergency situations?
VERBATIM ANSWER: Under the EUA we don't do a formal categorization but we authorize for specific settings which is sort of parallel to that CLIA categorization that we would do on a full marketing submission. But their - that does fall under FDA, the determining what settings a test can be used in under that authorization. The CLIA and CMS side is, you know, authorized on the CLIA side authorizing or certifying the labs for a specific level of testing and on the reimbursement and payment side of things determining what gets paid for.
SPEAKER QUESTION: Maria Ramos
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test categorization, FDA vs CLIA roles
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: For the clinical evaluation study of an anterior nasal swab antigen test for home use, the comparator should not be a saliva PCR test, correct?
CLARIFIED ANSWER: The FDA confirms that the comparator should not be a saliva PCR test for the clinical evaluation of an anterior nasal swab antigen test for home use.
VERBATIM QUESTION: For the clinical evaluation study of an anterior nasal swab antigen test for home use, the comparator should not be a saliva PCR test, correct?
VERBATIM ANSWER: Correct.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator for antigen test, Saliva PCR test
REVIEW FLAG: False

QA Block 15-1
CLARIFIED QUESTION: What is the FDA policy for receiving EUA submissions for antibody tests?
CLARIFIED ANSWER: The FDA continues to review EUA submissions for serology tests, including point-of-care, home collection, and high-throughput central lab tests if they are complete. However, lateral flow assays validated only for high-complexity labs are not currently prioritized.
VERBATIM QUESTION: What is the FDA policy for receiving EUA submissions for antibody tests?
VERBATIM ANSWER: That's incorrect on serology tests but we are on - if a test is not high throughput we are declining to review as part of a prioritization process. So if someone say has a lateral flow assay and they're only validating it for a high complexity lab that's not currently meeting our priority. Serology tests that are point of care home collection we're still reviewing if they are complete applications. And if they are high throughput tests, central lab tests as we've authorized a number of them, we are continuing to review those. So I'm not sure where you get your information but it's not correct.
SPEAKER QUESTION: Michael Zhang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submissions, Antibody tests, FDA prioritization
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: Does the FDA prioritize high throughput tests over lateral flow assays for EUA review?
CLARIFIED ANSWER: The FDA prioritizes high-throughput tests for EUA review and does not prioritize lateral flow assays validated only for high-complexity labs. Point-of-care and home collection serology tests with complete applications are also still reviewed.
VERBATIM QUESTION: Does the FDA prioritize high throughput tests over lateral flow assays for EUA review?
VERBATIM ANSWER: We are on - if a test is not high throughput we are declining to review as part of a prioritization process. So if someone say has a lateral flow assay and they're only validating it for a high complexity lab that's not currently meeting our priority. Serology tests that are point of care home collection we're still reviewing if they are complete applications. And if they are high throughput tests, central lab tests as we've authorized a number of them, we are continuing to review those.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test prioritization, high-throughput tests, lateral flow assays
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 17:05:58 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 15
##### Explicit Questions Extraction
QE 1-1: Do saliva collection devices or specimens added to VTM prior to testing need an EUA?

##### Implicit Questions Extraction
QI 1-1: What are the FDA's current priorities for COVID-19 diagnostic testing?
QI 1-2: Are amendments such as those for pooling and asymptomatic screening considered high priorities for FDA review?
QI 1-3: How should test developers approach obtaining feedback on plans for converting to full authorization if they submit a Pre-Submission (Pre-Sub)?
QI 1-4: What types of Pre-Submissions is the FDA currently reviewing for COVID-related diagnostics?
QI 1-5: What timelines should developers expect for MDUFA reviews, given the agency's stated workload challenges?
QI 1-6: What options are available for developers interested in long-term market presence of SARS CoV-2 molecular tests under the 510k pathway?
QI 1-7: What is required for developers to prepare for full authorization of COVID-19 diagnostic tests, including sample banking and validation studies?
QI 1-8: How does the FDA recommend developers address potential difficulties in obtaining positive samples for validation as infection rates decline?
QI 1-9: What pathways (e.g., De Novo or 510k) are available for serology and antigen test submissions, and how does this impact subsequent submissions?
QI 1-10: What companion diagnostic or breakthrough requests are still being reviewed under the ongoing workload pressures?
QI 1-11: Where can developers find recommendations or templates to guide analytical and clinical studies for saliva-based diagnostic tests?

#### Section 2 of 15
##### Explicit Questions Extraction
QE 2-1: Is it acceptable to perform a clinical study for a lateral flow rapid antigen test in a home setting instead of a simulated home environment?
QE 2-2: Would FDA allow the use of a saliva-based comparator test even though the lateral flow rapid antigen test in question uses a nasal sample?
QE 2-3: What type of comparator does the FDA recommend for a lateral flow rapid antigen test clinical study with nasal samples?
QE 2-4: How should developers address the concern of which sample is taken first in studies involving swabs for anterior nares?
QE 2-5: Should developers send a pre-EUA with their study design and check the comparator selection with FDA prior to initiating the study?
QE 2-6: What is the recommended time gap between the first collection and the second collection to minimize sensitivity loss for both the comparator and the test device?

##### Implicit Questions Extraction
QI 2-1: Which high-sensitivity PCR tests are authorized for use as comparators in home collection studies?
QI 2-2: Does the randomized collection process need to follow specific guidelines beyond alternation of order?
QI 2-3: What are the criteria for an authorized home collection kit to be suitable for use in this context?
QI 2-4: Are there specific recommendations for ensuring integrity of samples when mailing kits to participants in clinical studies?
QI 2-5: How can developers document and confirm adherence to the recommended collection procedures for swabs?

#### Section 3 of 15
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 3-1: What validation studies should test developers conduct for antigen test kits?
QI 3-2: Is the NCI test evaluation program exclusively for serology tests?
QI 3-3: If antigen test sample banks are challenging to create, what alternatives does FDA recommend?
QI 3-4: What role does the RADx program play in supporting the development of antigen test validation methods?
QI 3-5: How can test developers mitigate challenges associated with antigen tests that do not use VTM?
QI 3-6: What methods can be used to assess the potential impact of mutations and variants on antigen test performance?

#### Section 4 of 15
##### Explicit Questions Extraction
QE 4-1: Can recombinant or purified antigens spiked in negative clinical media be used for analytical performance testing of an antigen test?
QE 4-2: Can laboratory-based analytical performance testing, such as stability and limit of detection, be performed outside of the United States?

##### Implicit Questions Extraction
QI 4-1: Why is the use of recombinant or purified antigens not acceptable for validation activities?
QI 4-2: What challenges do recombinant or purified antigens present in correlating with real-world performance?
QI 4-3: What should developers include in detailed protocols for laboratory-based analytical performance testing conducted outside the US?
QI 4-4: Can recombinant or engineered antigens be used to evaluate the performance of tests with respect to specific mutations or variants?
QI 4-5: How can developers approach using recombinant antigen production to address potential FDA concerns?

#### Section 5 of 15
##### Explicit Questions Extraction
QE 5-1: How many samples of each SARS-CoV-2 variant are required to be evaluated for monitoring the performance of a lateral flow antibody test?
QE 5-2: Is there a specific method required for the confirmation of positive samples in relation to monitoring SARS-CoV-2 variant performance?

##### Implicit Questions Extraction
QI 5-1: What specific elements should a plan for monitoring new and emerging SARS-CoV-2 viral mutations and variants include in an EUA request?
QI 5-2: How should developers assess the potential impact of identified prevalent or clinically significant variants on the performance of their tests?
QI 5-3: What information should be provided to mitigate the risk of unknown performance in samples from individuals with prevalent variants?
QI 5-4: What details should be included when describing how serology samples were selected and characterized for variant evaluation?
QI 5-5: What sequencing method validation details, such as inclusivity and limit of detection, should be included when submitting variant data?
QI 5-6: How should developers describe the sequence analysis steps used to identify mutations in their submissions?

#### Section 6 of 15
##### Explicit Questions Extraction
QE 6-1: Is FDA going to be updating the antigen test template because of the development of mutations 1051 and D399N, even though their prevalence appears to be very low?
QE 6-2: Does FDA expect that a lab conducting analytical work outside the US should be GLP or would ISO 17025 be acceptable?
QE 6-3: How many matrices are expected to be tested for a nasal swab antigen test for at-home use, as it is unclear in Part J Part 1 of the template?

##### Implicit Questions Extraction
QI 6-1: What is the threshold of mutation prevalence that requires the FDA to update its guidance or website?
QI 6-2: How does the FDA define a significant drop in test performance (e.g., 5%) due to mutations?
QI 6-3: What steps should developers take if their antigen or molecular test is suspected to be affected by a low-prevalence mutation?
QI 6-4: Does the FDA provide detailed guidance on study plan formats for analytical studies?
QI 6-5: Are there any specific criteria for documenting study designs for EUA submissions?
QI 6-6: Can developers validate additional sample types even if initial performance requirements are met with one sample matrix?
QI 6-7: Is there flexibility in using different sample matrices provided they are properly validated?

#### Section 7 of 15
##### Explicit Questions Extraction
QE 7-1: What would be acceptable to use as the clinical matrix for a saliva antigen test?
QE 7-2: Can artificial saliva, fresh saliva, or commercially sourced saliva be used as the clinical matrix for a saliva antigen test?
QE 7-3: For the clinical evaluation, is it acceptable to use banked samples if it is difficult to obtain enough positive samples for antigen tests?

##### Implicit Questions Extraction
QI 7-1: What are the FDA's general expectations for submitting a pre-EUA for saliva-based antigen tests?
QI 7-2: Are contrived samples acceptable for analytical studies involving saliva-based tests?
QI 7-3: Does the FDA have specific recommendations for validating saliva antigen tests, given their challenging nature?
QI 7-4: What is the threshold for the amount of virus in saliva needed for effective antigen testing?
QI 7-5: How does the freeze-thaw process impact the sensitivity of antigen-based tests compared to molecular tests?
QI 7-6: What flexibility can be requested in a pre-EUA submission for antigen tests that do not align with standard FDA recommendations?
QI 7-7: Why are freeze-thaw studies required for molecular testing and how do they differ from the requirements for antigen testing?

#### Section 8 of 15
##### Explicit Questions Extraction
QE 8-1: When will the decision summary for the BioFire de novo assay be made available?
QE 8-2: Will the decision summary for the BioFire de novo assay definitely be made available?

##### Implicit Questions Extraction
QI 8-1: What is the protocol for reviewing proprietary information before posting decision summaries?
QI 8-2: How can developers utilize the Pre-Sub process for achieving full authorization of COVID-19 diagnostic tests?
QI 8-3: What steps is the FDA taking to expedite the posting of decision summaries for authorized COVID-19 tests?

#### Section 9 of 15
##### Explicit Questions Extraction
QE 9-1: Can you restate the CDRH position on what is acceptable for a bio-repository test versus a live specimen for molecular and antibody tests?
QE 9-2: What are the sensitivity limit requirements for a centralized laboratory test versus a home use or point-of-care test?
QE 9-3: Would the sensitivity minimum limits be different for a home use or point-of-care test versus a centralized laboratory test?

##### Implicit Questions Extraction
QI 9-1: What are the requirements for conducting freeze-thaw studies on frozen samples to ensure accurate results?
QI 9-2: For point-of-care or home use tests, what additional considerations are necessary when using banked samples instead of live specimens?
QI 9-3: Does the FDA provide specific guidance for designing studies that mitigate bias when using banked samples for analytical or clinical studies?
QI 9-4: What are the thresholds or guidelines for over-the-counter (OTC) home molecular testing pathways?
QI 9-5: Does FDA have templates that provide detailed recommendations for using banked specimens in test validation?

#### Section 10 of 15
##### Explicit Questions Extraction
QE 10-1: Does the FDA priority for asymptomatic amendments also extend to new submissions for asymptomatic testing?
QE 10-2: If we resubmit a new EUA now with asymptomatic validation, would that be a higher priority?

##### Implicit Questions Extraction
QI 10-1: What is meant by 'high throughput' as a criterion for prioritized submissions?
QI 10-2: Are low-throughput tests being deprioritized for EUA submissions due to pandemic priorities?
QI 10-3: Does the FDA have a specific throughput template that developers need to adhere to for prioritization?
QI 10-4: What is the FDA's definition of 'access' in terms of point-of-care and in-home testing?
QI 10-5: Will tests that are moderate to high complexity but do not meet high-throughput requirements be deprioritized indefinitely?
QI 10-6: Is the full authorization pathway still available for tests that do not align with the current pandemic priorities?
QI 10-7: How long are MDUFA applications currently taking to review?
QI 10-8: Are pre-submissions being delayed compared to other application types?

#### Section 11 of 15
##### Explicit Questions Extraction
QE 11-1: Is the less than 1% variant mutation not being detected by the Quidel Sofia 2 instrument the reason Medicare is declining payment or re-categorizing it as moderately complex or high complexity?
QE 11-2: What role does the FDA play versus CLIA in re-categorizing testing devices?
QE 11-3: Can CLIA re-categorize testing devices?

##### Implicit Questions Extraction
QI 11-1: What are the differences between FDA's test settings categorization under EUA versus a full marketing authorization?
QI 11-2: How does the FDA handle test categorization under an EUA compared to non-emergency situations?
QI 11-3: What steps should developers take if encountering reimbursement issues with CMS regarding tests authorized for point-of-care use?
QI 11-4: What does it mean for a test to be 'deemed waived' under an EUA?
QI 11-5: How can developers determine if their test reimbursement issues are related to coding or administrative misunderstandings?
QI 11-6: What role does FDA play in test categorization when CMS changes payment policies or coding?
QI 11-7: How does the communication between FDA and CMS affect diagnostic test developers?

#### Section 12 of 15
##### Explicit Questions Extraction
QE 12-1: Do clinical research organization sites qualify as a point of care setting?

##### Implicit Questions Extraction
QI 12-1: What are the requirements or expectations for a setting to qualify as a point-of-care location?
QI 12-2: What factors does the FDA consider when determining if a facility other than a primary care clinic can be used in point-of-care studies?
QI 12-3: Is there a process to pre-determine the appropriateness of a facility for point-of-care studies before conducting a study?
QI 12-4: How can developers ensure that instructions for use and device robustness meet FDA requirements for point-of-care settings?

#### Section 13 of 15
##### Explicit Questions Extraction
QE 13-1: If a test is not on a high-throughput platform and cannot test at least 150 samples at once but can still test multiple samples, is it considered a lower priority than other point-of-care tests or high-throughput platform tests?
QE 13-2: Can you define high throughput in the context of diagnostic testing?
QE 13-3: Do developers need to check if their test meets high-throughput requirements through the pre-EUA process?

##### Implicit Questions Extraction
QI 13-1: What constitutes a test being categorized as "addressing unmet needs" from the FDA's perspective?
QI 13-2: Are neutralizing antibody tests currently considered a priority by the FDA?
QI 13-3: What are the thresholds for tests to be classified as point-of-care, home, or high-throughput under current FDA guidelines?
QI 13-4: Is the FDA prioritizing tests beyond the stated categories (home, point-of-care, high-throughput) depending on pandemic stages?
QI 13-5: Can developers provide a partial pre-EUA submission if they follow template recommendations?
QI 13-6: Will high-throughput test requirements change depending on future pandemic needs?

#### Section 14 of 15
##### Explicit Questions Extraction
QE 14-1: For an antigen rapid test for home use, if an adult collects a sample from another person such as a child, can that same adult then run the test on themselves and be counted in the self-test group, or do we need 100 unique patients?
QE 14-2: For the clinical evaluation study of an anterior nasal swab antigen test for home use, the comparator should not be a saliva PCR test, correct?
QE 14-3: Should the comparator for an anterior nasal swab antigen test for home use be only an anterior nasal swab PCR test, or could it also be a nasopharyngeal swab PCR test?
QE 14-4: Even if a saliva test is a high-sensitivity PCR test, is it not acceptable as a comparator because it is not the same sample type?

##### Implicit Questions Extraction
QI 14-1: How should test developers contact the FDA to verify if a comparator test is acceptable?
QI 14-2: What are the recommended sample collection methods for anterior nasal swabs during usability studies?
QI 14-3: For usability studies, how might having the same individual perform two roles (self-test and testing another person) impact the broader analysis of instructional usability?
QI 14-4: What are the potential issues associated with using saliva as a sample type for comparator tests?
QI 14-5: Why is it recommended to verify comparator test appropriateness with the FDA in advance?

#### Section 15 of 15
##### Explicit Questions Extraction
QE 15-1: What is the FDA policy for receiving EUA submissions for antibody tests?
QE 15-2: Are there plans to phase out EUA submissions for certain types of tests in the near future?

##### Implicit Questions Extraction
QI 15-1: What is the FDA's prioritization process for reviewing EUA submissions for COVID-19 tests?
QI 15-2: Does the FDA prioritize high throughput tests over lateral flow assays for EUA review?
QI 15-3: Under what conditions will the FDA continue reviewing EUA submissions for serology tests?
QI 15-4: Is the availability of home collection or point-of-care features a factor in EUA review prioritization for serology tests?
QI 15-5: Where can the presentation materials and transcript from today's town hall be accessed?
QI 15-6: How can participants provide feedback after the conclusion of the virtual town hall?
